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ABSTRACT 
 
 
Estimating the Burden of Neurocysticercosis in Mexico. (August 2010) 
Rachana Bhattarai, B.V.Sc. & A.H., Tribhuvan University, Nepal 
Chair of Advisory Committee: Dr. Christine Budke 
 
 
 Neurocysticercosis (NCC) is a parasitic disease caused by the larva of the 
zoonotic cestode Taenia solium. The objectives of this study were to evaluate the 
distribution of presenting clinical manifestations of NCC, to evaluate the socio-
demographic characteristics of NCC patients, to compare quality of life of individuals 
diagnosed with NCC with an age and sex matched control population and to estimate the 
non-monetary burden of NCC in Mexico. In order to accomplish these objectives, a case 
series of NCC patients was conducted in two neurology referral hospitals in Mexico 
City, Mexico during 2007-2008. Information on clinical manifestations associated with 
NCC was obtained via medical chart reviews of NCC patients. Information on socio-
demographic characteristics of NCC patients was obtained through the administration of 
questionnaires. In addition, a cross-sectional study was conducted to compare the quality 
of life of NCC patients to an age and sex matched control population using the short 
form 12 v2 (SF-12 v2) survey. Non-monetary burden of NCC in Mexico was estimated 
using disability adjusted life years (DALYs), incorporating morbidity due to both NCC-
associated epilepsy and severe headache and mortality due to NCC-associated epilepsy.  
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NCC patients presented to the neurology referral hospitals with numerous 
clinical manifestations, with severe headache and epilepsy being the most common. 
Lack of knowledge of T. solium transmission was common among NCC patients, with 
25% of patients not knowledgeable about tapeworm infections in humans. Of those that 
were aware that tapeworm infections do occur, 57% were not aware of how the worms 
were transmitted to humans. The SF-12 v2 general health survey showed that individuals 
with NCC had a significantly lower score for all eight domains of health evaluated 
(physical functioning, role physical, bodily pain, vitality, general health, social 
functioning, role emotional and mental health) compared with the age and sex matched 
population from the same region (p< 0.05). The mean total number of DALYs lost due 
to NCC in Mexico was estimated to be 99,866 (95% CR: 43,187 –189,182), with a mean 
of 0.95 (95% CR: 0.4–1.8) DALYs lost per thousand persons per year. 
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1. INTRODUCTION 
 
 
 
Neurocysticercosis (NCC) is a major public health problem caused by the larva 
of the zoonotic cestode Taenia solium. Humans are the definite hosts of T. solium.  The 
parasite needs two hosts to complete its life cycle.  Pigs act as intermediate hosts and 
harbor cysticerci in different parts of the body, but mostly in the skeletal and cardiac 
muscles and the brain (cysticercosis). Humans become infected with the tapeworm form 
(taeniasis) by ingesting undercooked pork containing T. solium cysticerci. Eggs and/or 
mature proglottids of the tapeworm are regularly excreted by human tapeworm carriers. 
The tapeworm can shed up to 300,000 eggs daily [1].  Humans can also act as 
intermediate hosts after ingesting the eggs of T. solium leading to cysticercosis and/or 
NCC [2]. 
Neurocysticercosis occurs when immature T. solium larvae migrate to the central 
nervous system. When NCC manifests, it is most often in the form of acute seizures, 
epilepsy, severe progressively worsening headaches, or focal deficits. Less often it will 
present as cranial hypertension, hydrocephalus, stroke or dementia [3,4].  The condition 
is common in many developing countries, where sanitation and meat inspection 
infrastructure are lacking [5]. This disease is predominantly found and considered 
endemic in Latin American, Asian and African countries [6].  However, it is now being 
seen in other regions due to an increasing flow of immigrants from endemic areas who 
may have taeniasis [7,8].  Two previous studies conducted in Africa evaluated the  
_____________ 
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socio-economic burden of cysticercosis and found it to be a serious public health 
problem causing morbidity as well as financial loss [9,10].  NCC is believed to be one of 
the main causes of late onset epilepsy in developing countries [11,12] and a recent meta-
analysis of published studies  estimated that 29.6% (95%CI: 23.5%-36.1%) of epilepsy 
cases in NCC endemic countries are associated with NCC lesions as identified by 
neuroimaging [13].  NCC may also act as a risk factor for stroke [14] and migraine-type 
headaches [15].  
The Global Burden of Disease (GBD) Study was conducted to evaluate the non-
monetary burden of a variety of infectious and non-infectious conditions on pre-defined 
regions of the world [16,17]. The approach combined estimates of mortality and 
morbidity for a population into a single measure of disease burden called the disability 
adjusted life year (DALY). The DALY is a summary measure of population health that 
assesses the disability and early age mortality associated with the condition of interest. 
DALYs measure the gap in years between age at death and some standard age before 
which death is considered premature, in addition to time lived in states other than 
excellent health; they are obtained by summing years of life lost (YLL) from premature 
death and healthy years lost due to disability (YLD).  The DALY is a negative concept 
and one DALY is considered the equivalent of one year of healthy life lost. DALYs have 
been used to measure disease burden in both developed and developing countries [9,18]. 
Evaluation of the number of DALYs lost is then used to set health service and health 
research priorities, identify disadvantaged groups and target health interventions [16]. 
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Although NCC is endemic in many areas of the world and believed to be 
associated with considerable economic losses, very few studies have been conducted to 
evaluate the burden of NCC and there are no estimates from Mexico. One study in 
Cameroon revealed that the number of DALYs lost due to NCC was higher than a 
number of other neglected tropical diseases in sub-Saharan Africa such as 
trypanosomiasis and schistosomiasis [9]. However, this estimate only evaluated disease 
burden due to NCC-associated epilepsy, therefore underestimating the true impact of the 
disease. In addition, this study used serology for the diagnosis of NCC, which has been 
shown to have a poor performance in detecting cases. Another study conducted in South 
Africa revealed high financial losses associated with cysticercosis [10]. This study also 
considered epilepsy as the only clinical manifestation of NCC and thus underestimated 
the impact of financial loss associated with the disease. The true health burden of NCC 
in endemic areas likely differs substantially from country to country. Therefore, more 
comprehensive studies are needed to estimate the actual burden of NCC in endemic 
areas and specific countries, such as Mexico, in order to allocate resources for health 
interventions. This study provides the first estimate of the non-monetary burden of NCC 
in Mexico using the DALY.  
 4 
 
2. BACKGROUND AND SIGNIFICANCE 
 
 
 
NCC and taeniasis have long been recognized. From 1100 - 1800 AD, the adult 
and larval stages of T. solium were not considered the same species. In the late 19
th
 
century, cysticercus, formerly known as Cysticercus cellulosae, was demonstrated to be 
the larval form of T. solium. Later, in 1973, after the development of improved 
neuroimaging techniques and other immunological diagnostic methods, the 
epidemiology of T. solium was better established [2].  
NCC is still common in developing countries and is considered an emerging 
disease in many developed countries due to increased immigration from endemic areas 
[7,8]. In a study conducted in the United States in 2003, 84.6% of 221 NCC patients 
were foreign born and 62.0% had emigrated from Mexico [7]. The T. solium life cycle 
can rarely be completed in developed countries due to good environmental sanitation 
and highly regulated inspection of pig carcasses [19]. 
 
2.1. Life cycle, pathogenesis and transmission of Taenia solium 
T. solium belongs to the phylum Platyhelminthes, class Cestoides, family 
Taeniidae. The adult T. solium has a scolex that consists of four suckers and a rostellum 
with a double crown of hooks, an unsegmented narrow neck and a large body formed by 
many proglottids. The entire body is called the strobila. The adult worm is found in the 
small intestines of humans where it attaches to the intestinal wall by its suckers and 
hooks and may measure up to 10 – 30 feet in length. Infected humans excrete thousands 
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of eggs and gravid proglottids, which are very resistant to adverse environmental 
conditions. It is believed that eggs can remain viable for up to two months in water, soil 
and vegetation in a humid and warm environment. The condition caused by adult T. 
solium infection is known as taeniasis [2].  
Pigs, the intermediate hosts, become infected when they ingest eggs of T. solium 
that are shed in the feces of infected humans. Ingested larvae hatch in the intestine of the 
pig, penetrate the intestinal mucosa, reach the blood stream and migrate to tissues 
including muscle [2]. Pigs acquire cysticercosis mainly in endemic areas where they 
have access to human feces [20]. In some countries, human feces are fed directly to pigs 
believing that pigs fed human feces produce better quality pork [20,21]. 
Humans can become infected with T. solium in two ways (Figure 1). First, a 
person may act as a definitive host when ingesting raw or undercooked pork infected 
with viable cysticerci. The scolex of the larva emerges from the cyst and attaches to the 
wall of the small intestine. Within three months, an adult tapeworm develops and starts 
to produce proglottids. Humans can also act as intermediate hosts if they ingest the eggs 
of T. solium via contaminated food. After reaching the small intestine, eggs hatch and 
the embryos (oncospheres) migrate through the mucosa to enter the circulation which 
then carries the larvae to various tissues, including the Central Nervous System (CNS), 
eyes and striated muscle. After reaching these sites, oncospheres evolve to the vesicular 
stage and are called cysticerci [4] (Figure 1).  
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Figure 1: Life cycle of Taenia solium. 
 
 
2.2 Pathological changes of the central nervous system due to NCC 
Neurocysticercosis is the condition that occurs when cysticerci reach the brain 
parenchyma, the subarachnoid space, the ventricular system or the spinal cord and 
produces clinical manifestations. Cysticerci within the brain parenchyma usually 
measure around 1 cm and tend to lodge in the cerebral cortex or basal ganglia [4]. After 
the parasite enters the CNS, it changes into a viable stage (i.e., vesicular stage) where it 
stimulates the host’s immunological response. Inflammatory reaction around cysticerci 
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appears due to the host’s immunological response and is composed of lymphocytes, 
plasma cells and eosinophils. This reaction is usually associated with some degree of 
edema and gliosis, which varies according to the stage of the parasite [4,6]. The severity 
of the tissue changes depends on the stage of the parasites’ development and their 
location within the central nervous system [2]. 
Meningeal cysticerci may cause an intense inflammatory reaction within the 
subarachnoid space, forming a dense exudate which is composed of collagen fibers, 
lymphocytes, giant cells, eosinophils and hyalinized parasitic membranes. This causes 
thickening of the leptomeninges at the base of the skull from the optochiasmatic region 
to the foramen region [2]. The exudate usually entraps the optic chiasm, as well as 
cranial nerves arising from the brain stem, producing visual defects and other nerve 
dysfunction. The thickened leptomeninges may occlude the foramen of Luschka and 
Magendie leading to hydrocephalus. Blood vessels may be affected by inflammatory 
reaction and the inflammatory cells may invade walls of small penetrating arteries 
leading to a proliferative endarteritis with occlusion of the lumen which may result in 
cerebral infarction [22,23]. 
Ventricular cysticerci also induce a local inflammatory reaction if they are 
attached to the choroid plexus or the ventricular wall. Ependymal cells may proliferate 
and block cerebrospinal fluid transit at the cerebral aqueduct or Monro’s foramina 
causing obstructive hydrocephalus [24,25] resulting in increased morbidity and mortality 
compared to parenchymal cysticerci [26]. 
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2.3 Clinical manifestations 
 Clinical signs depend on the number and location of cysts as well as the host’s 
immune response to the cysts. Epilepsy, hydrocephalus, severe headaches, and increased 
intracranial pressure are among the most commonly reported clinical manifestations 
[3,4].  
 
Epilepsy 
 NCC has been reported as a major cause of late onset epilepsy in T. solium 
endemic areas of the world [11,27]. Epilepsy may occur when a cyst is in an active form, 
(i.e., viable or degenerating) [11,28] or in a calcified form [29]. Seizures, due to NCC, 
are most commonly generalized tonic, clonic or simple partial. Few cases present with 
complex partial or myoclonic seizures [30,31]. Severity of seizures has not been 
correlated with intensity of infection [26] and single calcifications were often found in 
patients with seizures in a study conducted in India [28]. Parenchymal cysts appear to be 
common in patients with epilepsy [32]. 
 
Increased intracranial pressure/hydrocephalus 
 Increased intracranial pressure is another symptom of NCC due to obstructive 
hydrocephalus. Ventricular or cisternal cysts, and chronic cysticercus meningitis are 
common causes of hydrocephalus and increased intracranial hypertension [33]. Mobile 
deformable cysticercal cysts in the posterior portion of the third ventricle can cause 
intermittent intracranial hypertension due to a ball valve mechanism known as Bruns 
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Syndrome [25]. Massive cysticerci infections of the brain parenchyma can also increase 
intracranial pressure. However, the pathology is induced by an intense inflammatory 
immune response rather than by the physical presence of the cysts. A study conducted in 
Mexico in 1987 reported that cysticerci of the brain parenchyma were more common in 
young females and were characterized by sub-acute encephalitis associated with 
headaches, seizures, vomiting, diminution of visual acuity and papilledema [34]. 
 
Cerebrovascular complications 
 Cerebrovascular complications include transient ischemic attacks, lacunar 
infarcts, large cerebral infarcts and brain hemorrhage [29,35,36]. Occlusion of the small 
cortical or penetrating vessels at the base of the brain caused by arteriopathy has been 
reported as the most common mechanism of stroke among 31 NCC cases presenting 
with stroke in Mexico in 1985 [37]. Lacunar infarcts are frequently located in the area of 
the lenticulostriate branches of the anterior or middle cerebral artery and produce 
occlusive endarteritis within the subarachnoid space that is triggered by meningeal 
cysticerci [38]. This condition produces typical lacunar syndromes such as pure motor 
hemiparesis and ataxic hemiparesis, which is difficult to distinguish from those 
syndromes caused by atherosclerosis [39]. The most common vessels reported to be 
involved in cerebral infarcts among 28 NCC patients in Mexico in 1997 were the middle 
cerebral artery and the posterior cerebral artery [36]. Different types of intracranial 
hemorrhage, such as intracystic hemorrhage and subarachnoid hemorrhage, have also 
been documented with NCC [40].   
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Psychiatric disorders 
Patients with NCC may present with psychiatric disorders. In a study conducted 
in Brazil between January 1993 and April 1994,  depression syndromes were the most 
common clinical manifestations in 38 NCC patients presenting to a neurology referral 
hospital [41].  However, the primary study looking at these manifestations did not have a 
control group and did not take into account confounding variables such as illiteracy, high 
prevalence of seizures and use of anticonvulsant medications. Therefore, results might 
be biased. Other reported manifestations include poor performance on 
neuropsychological testing, dementia, psychotic episodes characterized by confusion, 
paranoid ideation, psychomotor agitation, and/or violent behavior [42]. Although 
dementia is a less common clinical manifestation of NCC, it can occur in patients with 
untreated NCC. NCC-related dementia was shown to be associated with older age, lower 
education level and increased number of parasitic lesions in the brain in a study 
conducted in 14 NCC patients in  Mexico during 2005 [43]. However, the same test was 
used to evaluate dementia in educated and less educated NCC patients. Therefore, it 
might have overestimated the relationship between dementia and less educated people. 
NCC-associated dementia has been reported to be reversible by regular treatment of 
NCC with anticysticercal drugs, with patients experiencing noticeable recovery of 
cognitive functioning [43]. However, this conclusion must be interpreted with care since 
there was no placebo control group with which to compare the results. 
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Severe headache 
Severe headache is also a common manifestation presented by NCC patients in 
neurological hospitals. Both abrupt and chronic obstruction of cerebral spinal fluid 
(CSF) can result in headache. Abrupt intermittent obstruction of the interventricular CSF 
flow by the cyst produces symptoms which can last several hours to days. Obstruction 
may occur in the foramen of Monro, the  third ventricle, the aqueduct of Sylvius or the 
fourth ventricle [44].  
 
2.4 Diagnostic techniques 
 Before the wide scale use of modern neuroimaging methods, radiological 
procedures such as plain roentgenograms, pneumoencephalograms, cerebral angiography 
and myelography were considered helpful diagnostic tools for NCC. Computed 
tomography (CT) and magnetic resonance imaging (MRI) are two neuroimaging 
techniques that have improved the accuracy of diagnosis in recent years [45]. Both of 
these techniques provide evidence concerning the number and topography of lesions, 
their stage of involution and the degree of host inflammatory response against cysticerci 
[46]. Cystic lesions showing the scolex in the nodule and multiple punctuated 
calcifications are pathognomonic of NCC. However, single or multiple enhancing 
lesions are not specific to NCC and may represent, for example, pyogenic brain 
abscesses, fungal abscesses, tuberculosis, Toxoplasma abscesses and primary or 
metastatic brain tumors [2].  
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Diagnostic criteria used for NCC is divided into absolute, major, minor and 
epidemiologic [47]. Parasite histologic examination from biopsy of a brain or spinal cord 
lesion, CT scan or MRI showing a scolex in a cystic lesions and direct visualization of 
sub-retinal parasites by funduscopic examination are considered pathognomonic and, 
therefore, absolute criteria for diagnosis of NCC. Major criteria are CT scan or MRI 
showing highly suggestive NCC lesions, the detection of anticysticercal antibodies by 
positive serum enzyme-linked immunoelectrotransfer blot assay (EITB), resolution of 
intracranial cystic lesions after therapy with albendazole or praziquantel and 
spontaneous resolution of small single enhancing lesions. Minor criteria are 
neuroimaging studies showing lesions compatible with NCC, clinical manifestations 
suggestive of NCC, positive CSF enzyme linked immunosorbent assay (ELISA) for 
detection of anticysticercal antibodies or cysticercal antigens and cysticercosis outside 
the CNS. Lastly, epidemiologic criteria are evidence of a household contact with T. 
solium infection, individuals coming from or living in an area where cysticercosis is 
endemic and history of frequent travel to disease-endemic areas.  
According to Del Brutto et al. (2001), presence of one absolute criteria or 
presence of two major plus one minor and one epidemiologic criteria are definitive 
diagnostic criteria while presence of one major plus two minor criteria, presence of one 
major plus one minor and one epidemiologic criteria and presence of three minor plus 
one epidemiologic criterion are probable diagnostic criteria for NCC [47].  
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Immunological tests 
 Different immunological tests are available for the detection of anticysticercal 
antibodies and antigens in serum, saliva and CSF and are valuable for patients with 
suspected NCC, but should not be used alone as confirmatory tests. The antibody 
detection tests include the complement fixation test, hemagglutination, 
radioimmunoassay, enzyme linked immunosorbent assay (ELISA), dipstick-ELISA, 
latex agglutination and immunoblot techniques. Many of these tests (e.g., the 
complement fixation test, the ELISA and the immunoblot test) are highly sensitive for 
subarachnoid NCC [48]. However, sensitivity decreases when the lesions are inactive 
and are not in contact with the subarachnoid space. This is because large numbers of 
immunoglobulins are synthesized due to the contact of lesions with the subarachnoid 
space. Cross-reaction is known to occur with other helminth parasites for the ELISA 
[49]. Tsang  et al., (1989) reported that the EITB has a 100% specificity and 70%-90% 
sensitivity in cysticercosis patients [50]. However, sensitivity of this test is low in 
patients with single cysts in the brain [51]. On the other hand, antibody detection has two 
major drawbacks. First, the test may be positive when a person has exposure to the 
parasite without the presence of viable infection and second, the antibodies may persist 
long after the parasite has been eliminated by immune mechanisms. Another type of 
immunological test is the antigen detection test. The sensitivity of antigen-detecting 
ELISA has been reported to be 85% for detecting NCC patients [52]. However, this 
study was only conducted on individuals who were seropositive on EITB. 
 
 14 
 
Neuroimaging techniques 
In subarachnoid NCC, CT and MRI findings may include hydrocephalus, 
abnormal enhancement of the leptomeninges, subarachnoid cystic lesions and cerebral 
infarcts [23]. Most of these findings are non-specific and may be observed in 
tuberculous meningitis, sarcomatous meningitis or fungal meningitis. 
In NCC with ventricular cysticerci, CT and MRI findings show a distorted 
anatomy of the ventricular system, with cysts located in the ventricles. Due to the same 
radiodensity of lesions and CSF, these lesions cannot be seen clearly on a CT scan [53]. 
MRI is more sensitive and is superior to CT scans in finding multiple cystic lesions, 
protoscoleces and differential ring enhancements [46]. However, one important 
shortcoming of MRI is its failure to detect parenchymal calcification [54]. 
 
2.5 NCC in Mexico 
Mexico is the third largest country in Latin America, with a 2008 population of 
almost 109 million and an annual population growth rate of 1.1%. The official literacy 
rate is 89.6%. CIA World Fact book reports that health care personnel and facilities are 
generally concentrated in urban areas and infections, including parasitic diseases, still 
are responsible for numerous deaths [55]. 
NCC is present in Mexico, with literature-reported prevalences of 4.9% - 10.8% 
in endemic areas [20,56,57,58]. However, not all of the diagnostic criteria used in these 
studies are uniform and reliable. In Xoxocotla, Morelos state of south-central Mexico, 
the reported seroprevalence was 10.8% in 1988 [20] . However, this study was 
 15 
 
conducted twenty years ago and might not represent the present situation in this region 
of Mexico. In addition, a person can be seropositive if he or she has a cyst in another 
part of the body. In Tepetzezintla, Puebla state in central Mexico, a prevalence of 9.1% 
was confirmed by CT in 2003 [56]. All of the cases from Tepetzezintla had silent 
calcified lesions.  In the 1970s, at the Instituto Nacional de Neurologia y Neurocirugia in 
Mexico City, a substantial number of patients admitted were diagnosed with NCC, with 
NCC representing the third most common reason for admission [2]. In addition, NCC 
was found in 1.3-3.1% of autopsies performed in four large hospitals in Mexico City for 
the years 1942-1974 [2].  
Two studies have shown that NCC cases tend to be numerous in those areas 
where T. solium carriers are present [20,59]. In 1988, the prevalence of tapeworm 
carriers was 1.3% and 5.8% in La Curva, Sinaloa state of Mexico and in Xoxocotla, 
Morelos state of Mexico, respectively [20,59]. However, this prevalence may include 
cases of T. saginata since the eggs of these tapeworms are only differentiable by PCR.  
In a study conducted in 2007, Taenia eggs were found in 24.2% of sampled areas 
(backyard, washboard, bucket, coral and kitchen) in the State of Puebla, Mexico, with 
the highest prevalence found in the spring [60]. Significantly higher numbers of Taenia 
eggs were found in kitchen samples compared to other places that were sampled. This 
indicates a high risk of infection with Taenia species within the household [60]. This 
study did not, however, identify the species of Taenia involved. Most animal species can 
carry Taenia, making the interpretation of those data in regard to T. solium difficult. 
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2.6 Quality of life associated with NCC infection 
 Quality of life assessment is used to measure changes in physical, mental and 
social health due to conditions and interventions that are influenced by a person’s 
experiences and perceptions. It can also be used to plan and evaluate the services needed 
for people with disabilities [61]. Among numerous quality of life surveys, the short form 
12 v2 health survey (SF-12 v2) (Quality Metric Inc., Lincoln, RI) is a short and easy to 
use tool to assess the quality of life of an individual. Ware et al. (2002) examined the 
validity and reliability of the SF 12v2 survey at the time of its development. They 
compared the results of the SF-12 v2 to that of the 1998 National Survey of Functional 
Health Status and 2000 Medical Outcomes Study [62]. Later, another study conducted 
by Cheak-Zamora et al. (2009) also evaluated the validity and reliability of the survey in 
the 2003-2004 Medical Expenditure Panel Survey [63]. Both studies found that the 
validity and reliability of the survey was high.  
The SF-12 v2 survey is considered a generic health survey because it can be used 
across age, disease and treatment groups. The survey is specifically designed for adults 
18 years of age and older and is available in multiple languages. The SF-12 v2 uses 
twelve questions to measure eight domains of functional health and well being. The 
eight domains of health assessed are physical functioning, role physical, bodily pain, 
general health, vitality, social functioning, role emotional and mental health. A brief 
description of each domain is found in Table 1.  
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Table 1: Descriptions of the health domains used in the SF-12 v2 quality of life 
survey [64]. 
 
Domain Description 
Physical functioning Degree to which health limits everyday physical activities 
Role physical Degree to which physical problems interfere with usual 
daily activities such as work or school 
Bodily pain  Degree of bodily pain 
General health Ratings of current health in general 
Vitality Ratings of energy level 
Social functioning Degree to which health interferes with social activities 
Role emotional Degree to which emotional problems interfere with usual 
daily activities such as school or work 
Mental health Degree to which health limits emotional well being, 
including depression, anxiety and positive well being 
 
 
The eight domains can be aggregated into two summary measures: the Physical 
Component Summary (PCS) and the Mental Component Summary (MCS). PCS weights 
more heavily physical functioning, role physical and bodily pain and MCS gives greater 
weight to mental health, social functioning and role emotional. General health and 
Vitality load fairly evenly on both component summaries [65]. 
The SF-12 v2 is a useful tool to compare the health scores of patients with an age 
and sex matched population from the same region[62]. Numerous studies have used the 
SF-12 v2 survey to compare different populations for conditions such as echinococcosis 
and migraine [66,67]. However, no previous studies have used this health survey to 
compare NCC patients with a comparison group. 
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2.7 Global Burden of Disease (GBD) Study 
Prior to the 1990s, available information on mortality and health related 
problems in populations were largely incomplete and inconsistent. Thus, a framework 
for integrating, validating, analyzing and disseminating such information was needed to 
assess the comparative importance of diseases and injuries causing premature death, loss 
of health and disability in different populations. Therefore, the Global Burden of Disease 
(GBD) Study was initiated by the World Health Organization (WHO) and World Bank 
in 1993 to generate comprehensive and internally consistent estimates of mortality and 
morbidity by age, sex and region. The goal of this study was to measure the total loss of 
health resulting from diseases and injuries worldwide in a comparable way [68]. The 
GBD Study was the first large scale initiative to emphasize non-fatal health outcomes, 
which had not previously received much attention from health policy makers.  This 
information could then be used to set health service and health research priorities, 
identify disadvantaged groups and target heath interventions [17]. The first GBD Study 
(GBD 1990) assessed the burden of 107 diseases and injuries and ten selected risk 
factors for the world. This and subsequent GBD studies used a common metric, the 
disability adjusted life year (DALY), for burden of disease assessment. 
 
Disability adjusted life years (DALYs) 
 A new metric, the disability adjusted life year (DALY), was introduced by the 
GBD Study to assess the burden of disease consistently across diseases, risk factors and 
regions. DALYs are used to help quantify the burden of disease and the effectiveness of 
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health interventions. The DALY is a time based measure, which combines years of life 
lost due to premature mortality (YLL) and years of life lost due to time lived in a 
disability state (YLD). This metric calculates the years of life lost due to premature 
mortality by comparing study population life spans to the average life expectancy of the 
population of Japan, which has one of the longest known life expectancies. Therefore, it 
is a measurement of the gap between current health status and the ideal situation where 
everyone is free of disease and disability [68]. The formulas used for the calculation of 
YLL and YLD are described below: 
YLL = N * L……………………….Eq. 1 
where N = number of deaths per age-sex group, L = remaining life expectancy at age of 
death 
YLD = I * DW * D………………….Eq. 2 
where I = age and sex specific estimates of incidence, DW = disability weight, D = 
average duration of disability.  
 
Discounting  
 Discounting future time is a common concept in economic and social policy. In 
burden of disease estimations, a discount rate is applied so that future healthy life has 
less value than the net value of life today [69]. The subject of discounting is complex 
and several papers have been published in favor and against its use in the context of 
DALYs [69,70] and health outcomes. Figure 2 illustrates the effect of time on 
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discounting using the discrete discounting function (1/(1+r))
t  
where t denotes time in 
years and the discounting rates ( r ) values are 3%, 6% and 10%. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Effect of time, in years, on the discrete discounting function. 
 
 
Figure 2 shows that a 3% discount rate implies a year of healthy life gained in ten 
years is worth 26% less than one gained now and a 10% discount rate implies a year of 
healthy life gained in 10 year’s time is worth 61% less than one gained now. If we use a 
0% discount rate, the future is valued exactly as the present.  
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Age weighting 
 The GBD Study incorporated social preferences for the value of life lived during 
adulthood over life lived during childhood or later years. For DALYs used for the GBD 
Study, the value of life peaks at age 24.5 years when an age weighting value of 0.04 is 
used. Age weighting is based on the belief that there is a social preference to greater 
value the lives of young adults versus individuals in other age categories. This may be 
due to the belief that young adults have reached maturity, have been trained and are 
ready to contribute economically and productively to society for a greater amount of 
time.  The GBD Study [16] assumed an arbitrary continuous age weighting function F(C, 
age, β) for the weights at each age in the form: 
F(C,age,β) = C*age*e-β*age………………Eq. 3 
where β determines the importance of age weights and C is an adjustment constant. Only 
a narrow range of β provides reasonable age patterns (0.03 to 0.05). In the GBD Study, β 
was set to 0.04 and C set to 0.1658. The constant C was chosen because introducing 
unequal age weights does not change the global estimated burden of disease from the 
total and thus produces the same values as that of uniform age weights. Therefore, this 
constant should be changed if the age weighting function were to be changed. Figure 3 
illustrates the effect of age on weighting without the influence of C. The new Global 
Burden of Diseases Study, (the GBD 2010 Study) will not include age weighting in the 
DALY calculations. Therefore, the influence of age weighting will be eliminated. 
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Figure 3: Shape of age weighting function for β in the set (0.03, 0.04, 0.05). 
 
 
Disability weights 
The DALY metric measures disability through reduction in human functioning. 
Disability weights are allocated according to the opinion of experts on the ability to 
perform certain activities such as learning, working, feeding oneself, etc of people 
affected by a disease. Disability is placed on a uni-dimensional scale between 0 (perfect 
health) and 1 (death). Disability classes were defined between 0 and 1, with each 
subsequent class representing more severe disease. Disability weights of clinical 
manifestations were determined for the GBD Study by the person trade-off (PTO) 
method [69]. The PTO method is a way of estimating social preferences for different 
health states by asking people how many outcomes of one kind they believe are equal in 
social value to a certain number of outcomes of another kind. The GBD 2010 Study will 
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not use the PTO method for determining disability weight of clinical manifestations. 
Three major data collection activities proposed for determining disability weight are 
community assessment of selected sequelae using discrete choice methods, assessment 
by health professionals of all sequelae using ranking and visual analog scale methods 
and multimethod studies among highly educated respondents [71]. 
 
Pros and cons of DALYs 
 The use of DALYs remains a controversial issue. According to Anand (1997), 
DALYs understate the burden of disease of females relative to males if the gender gap of 
life expectancy is high as it uses the standard expectation of life at birth for a developed 
country which has a very small gender gap [70]. DALYs also measure the burden of 
disease without considering cultural or socioeconomic differentiation of tested 
populations so that it underestimates the disease burden in developing countries [72]. 
The GBD 2010 Study will try to take into account some of the disparity between 
regions. Even with these controversies, the DALY remains a widely used summary 
measure of population health.  
 DALYs have been used to measure disease burden in both developed and 
developing countries [9,18]. However, only one study has been conducted to evaluate 
the burden of NCC. In that study conducted in Cameroon, a high non-monetary and 
monetary burden due to cysticercosis was found, with an estimated 9.0 (95% CR 2.8 to 
20.4) DALYs lost per thousand person years and 194€ (95% CR 147 to 253) lost per 
case of NCC [9]. However, the total number of DALYs lost and total estimated cost 
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were most likely underestimated in the study, because the estimations were based on 
epilepsy as the only symptom of cysticercosis. On the other hand, it could have also been 
an overestimation since the authors used serology alone to diagnose NCC, which can 
lead to large numbers of false positives. This study also used prevalence data to estimate 
incidence which may or may not be appropriate and used disability weights from the 
GBD Study for epilepsy which also may not be appropriate for NCC. 
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3. MATERIALS AND METHODS 
 
 
 
3.1. Study population and design 
Source population 
 The source population included adults (>18 years old) in Mexico who have 
access to a formal health care system irrespective of social security coverage.  
 
Study population 
This study was conducted in the two major referral hospitals for adult 
neurological cases in Mexico City, Mexico, the Instituto Nacional de Neurologia y 
Neurocirugia (INNN) and the Hospital de Especialidades of the Instituto Mexicano del 
Seguro Social (IMSS). The INNN is a referral institute that accepts patients who do not 
have medical coverage through their employment. The IMSS is the largest social 
security institution in Mexico and provides medical services to patients with social 
security coverage.   
 
Study design 
This study is a case series of NCC patients representative of those seen in two 
neurology reference hospitals in Mexico City, Mexico. Consecutive NCC outpatients 
presenting with epilepsy, symptomatic recurrent acute crises, hydrocephalus, dementia, 
vasculitis, EVC and / or severe headache for more than 3 days were invited to participate 
in the study.  Those patients consenting to participate represented the case series of NCC 
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patients.  General and pig ownership questionnaires were administered to NCC 
outpatients in order to evaluate socio-demographic characteristics and knowledge about 
T. solium transmission. In addition, a cross-sectional study was conducted to compare 
SF-12 v2 health scores of the NCC outpatients included in the case series to an age–sex-
hospital-date matched comparison group of people accompanying neurological patients 
without NCC.  
 
Definition and selection of NCC cases 
 NCC patients were identified by the hospital staff from their databases. The 
diagnosis of NCC was that of the physicians who had taken care of the patient. All 
patients had at least one CT-scan of the brain and/or and MRI. An attempt was made to 
ask all NCC outpatients presenting with the symptoms mentioned above and who came 
to the INNN from July 17, 2007 to December 7, 2007 and to the IMSS from June 2, 
2008 to August 12, 2008 for their consent to participate in the study. All patients who 
provided written consent were interviewed by a trained member of the research team 
(e.g., a Mexican medical student, intern, or resident) at the time of their appointment. 
 
Definition and selection of non-NCC group (Controls) 
 An individual (e.g., a caregiver or close relative) who accompanied an outpatient 
to either the INNN or the IMSS who had not been diagnosed with NCC was considered 
as a possible control. To avoid confounding, controls were selected from individuals 
who accompanied non-related patients and paired with an NCC patient seen at the clinic 
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on the same day by sex, age (± 5 years) and hospital. This 1-to-1 matched control group 
was selected and interviewed in the hospital’s waiting area by a member of the research 
team after obtaining written consent.  
 
3.2 Description of manifestations associated with NCC cases 
 Intake forms were completed via medical chart reviews of all consenting NCC 
outpatients from the INNN and IMSS. Intake forms were also completed via chart 
reviews for consenting NCC patients who had been hospitalized at the INNN during 
2006 and 2007, but who did not have an outpatient appointment during the study dates 
(July 17, 2007 to December 7, 2007). The intake forms [Appendix A (English version) 
and D (Spanish version)] were used to obtain information on the medical problem(s) 
associated with NCC that caused the patient to be referred to the tertiary care hospital. 
Chart reviews took place between July 17, 2007 and December 7, 2007 at the INNN and 
between June 2, 2008 and August 12, 2008 at the IMSS, with data abstracted from 
January, 2002 to the date of abstraction by trained members of the research team (e.g., a 
Mexican medical student, intern, or resident).  The forms were prepared in English, 
translated into Spanish and back translated into English by two independent persons. All 
forms were piloted prior to use. In addition to the information on medical problems, age 
distribution and geographical distribution of patient residences were also evaluated using 
information obtained through chart reviews. 
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3.3 Description of socio-demographic characteristics of NCC cases  
 Two questionnaires [Appendix B and C (English version) and E and F (Spanish 
version)] were completed via patient interviews. A general questionnaire was completed 
by all consenting NCC outpatients and an additional pig questionnaire was completed by 
those individuals who raised pigs. The general questionnaire focused on socio-
demographic factors, knowledge about the life cycle of T. solium, as well as questions on 
care received by NCC patients. The second questionnaire focused on pig ownership and 
use. Both questionnaires were translated into Spanish, back-translated into English by 
two independent persons and pilot tested locally prior to use. 
The general questionnaire contained questions about the patient’s knowledge of 
the transmission of T. solium, socio-demographic factors of NCC cases and the cost 
related to care received by NCC patients with epilepsy in Mexico. This questionnaire 
contained 29 questions, with some questions having multiple sub-parts. Questions 
related to patient’s knowledge and socio-demographic characteristics were closed ended 
and cost related questions were open ended. The pig questionnaire contained information 
on breeds of pig raised by the patient, the purpose and/or use of these pigs and costs 
related to lost economic value due to cysticercosis.  The questionnaire consisted of 11 
questions, with all questions, except for cost-related questions, closed ended.  
 
3.4 Measurement of outcome (Quality of life) 
The Short Form 12 version 2 generic quality of life survey (SF-12 v2) was 
completed by participating NCC outpatients and controls. The SF-12 v2 survey 
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(Mexican Spanish version) was used to compare the health scores of NCC patients with 
an age (± 5 years) and sex matched control population from the same region [Appendix 
H (Spanish version)].  Twelve questions were used to assess eight domains of health in 
the survey: physical functioning, role physical, bodily pain, general health, vitality, 
social functioning, role emotional and mental health.  
All domains were checked for missing data for each patient. If more than four 
health domains were missing for any case or control, that case/control along with his or 
her matched control/case were not included in the analysis. Data were rescored for 
uniformity (i.e., positive health responses received higher scores) according to Quality 
Metric guidelines [62]. Raw scores were then transformed to a 0-100 scale in accordance 
with standard procedures [62]. This transformation converts the lowest and highest 
possible scores to zero and 100 and scores between these values represent the percentage 
of the total possible score achieved. Health scores for the NCC positive and control 
groups were compared for the overall population, for males and females separately, for 
long (diagnosed 6 or more years prior) and short (diagnosed less than 6 years prior) 
duration of NCC, for epilepsy and severe headache separately and across different age 
groups. 
The Physical Component Summary (PCS) and Mental Component Summary 
(MCS) were calculated by aggregating the eight domains of the SF-12 v2, transformed 
to z-scores and multiplied by their factor score coefficients, and standardized as t scores 
with a mean of 50 and standard deviation of 10 according to Quality Metric guidelines 
[62]. Due to lack of information on factor score coefficients for Mexico, mean, standard 
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deviation and factor score coefficients used to calculate the component scores were 
based upon the U.S. population. While using U.S. based norms may not be optimal, it 
does provide a basis of uniformity for cross-national comparison [73]. A higher score on 
both summary scales represents better functional health. 
 
3.5 Data management of chart review and health survey data 
 Information obtained from the chart reviews, questionnaires and SF-12 v2 survey 
forms was captured in paper form. Later, the information was entered into the Select 
Survey program (ClassApps Com., Overland Park, KS) and then exported into Excel 
(Microsoft Corp., Redmond, WA) spreadsheets for analysis. Paper copies of the 
completed chart reviews were kept in a locked filing cabinet at Texas A&M University, 
with access provided only to members of the research team. 
 
3.6 Statistical analysis of chart review and health survey data 
 Descriptive analyses of the data were performed using means, medians and 
proportions. Normality of the SF-12 v2 data was analyzed by the Shapiro-Wilk method. 
SF-12 v2 data was not normal. Therefore, the Mann-Whitney test was used to compare 
the health scores of the two populations. The distribution of health scores of NCC 
patients and controls were visually compared by drawing box plot graphs. 
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3.7 Ethical approval of chart review and health survey data 
This study received IRB approval from Texas A & M University (2006-0606), 
the INNN and the IMSS. The licensed (28408) SF-12 version 2 health survey (Mexican 
Spanish version) was used for the comparison of quality of life of NCC patients and 
controls. 
 
3.8 Non-monetary burden of NCC in Mexico 
Disability adjusted life years (DALYs) 
For the calculation of years of life lost due to premature mortality (YLL), 
standard life expectancies (life expectancy of 82.5 years at birth for women and a life 
expectancy of 80.0 years at birth for men) were used [16]. As in past GBD studies, 3% 
discounting and non uniform age weighting (β = 0.04 and C = 0.1658) were used [16]. 
These values were chosen so that the socioeconomic impact of NCC determined in this 
study can be compared with previous burden of disease estimates for other conditions.  
For the calculation of years of life lost due to premature NCC-associated epilepsy 
mortality (YLL), WHO 2004 mortality estimates for epilepsy were used [74]. Of these 
deaths, 30% were assumed to be associated with NCC, based on the findings of a recent 
systematic review of the association of NCC with epilepsy [13]. There is no published 
literature on NCC-associated severe headache deaths. Therefore, we assumed that no 
deaths occurred due to NCC-associated severe headache.  For the calculation of years of 
life lost due to time lived in a disability state (YLD), annual incident cases of NCC-
associated epilepsy and severe headache were needed. However, incidence of epilepsy 
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and severe headache due to NCC is not known in Mexico. Therefore, these parameters 
were estimated by dividing the prevalence of epilepsy and severe headache associated 
with NCC by the reported duration of epilepsy from GBD studies [75] and mean 
duration of NCC-associated severe headache from chart reviews. Prevalence of epilepsy 
and severe headache were obtained from available literature [76,77].  
 
Disability weights 
 Disability weights for NCC were not included in the original GBD Study or its 
subsequent updates. Therefore, to calculate the morbidity component of DALYs lost due 
to NCC, disability weights for treated and untreated groups for different clinical 
manifestations of NCC were estimated. Clinical manifestations reported by patients with 
NCC, in this study, included severe headache/migraine, epilepsy, stroke, dementia, 
hydrocephalus and increased intracranial pressure. Hydrocephalus and increased 
intracranial pressure were included in the severe headache category as headache is often 
a result of both hydrocephalus and increased intracranial pressure. Disability weights for 
severe headache were not included in previous GBD studies. Therefore, published 
disability weights for migraine were used as a surrogate for severe headaches. Disability 
weight for severe headache was not divided into age categories because of limited 
available data.  Due to the limited data on stroke and dementia, these manifestations 
were not included in the estimation of DALYs. Hence, only two manifestations (epilepsy 
and severe headache) were used to estimate the DALYs. Disability weights for epilepsy 
and severe headache used in this study are listed in Tables 2 and 3.  
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Table 2: Age specific disability weights (DWs) for treated and untreated forms of 
epilepsy.  
 
Parameter Mean 95% CI Distribution References 
DW for people between 0 and 4 
years of age not receiving an 
appropriate treatment 
0.099 0.021-0.225 Beta(3,27.3) [9,75] 
DW for people between 0 and 4 
years of age receiving an 
appropriate treatment 
0.041 0.003-0.124 Beta(1.5,35) [9,75] 
DW for people older than 5 
years of age not receiving an 
appropriate treatment 
0.15 0.033-0.331 Beta(3,17) [9,75] 
 
DW for people older than 5 
years of age receiving an 
appropriate treatment 
0.065 0.004-0.192 Beta(1.5,21.6) [9,75] 
 
 
Table 3: Disability weights (DWs) for treated and untreated forms of migraine/ 
severe headaches. 
 
Parameter Mean 95%CI Distribution References 
DW for people not receiving 
an appropriate treatment 
0.0275 0.025-0.03 Uniform 
(0.025,0.03) 
[78] 
DW for people receiving an 
appropriate treatment 
0.007 0.0063-0.0077 Uniform 
(0.0063,0.0077) 
[78] 
 
 
Duration of disease 
 Mean duration of disease varies according to the clinical manifestation associated 
with NCC.  Therefore, duration of disease was considered separately for epilepsy and 
severe headaches stratified by age and sex. Due to the lack of published data on the 
duration of NCC-associated epilepsy and severe headache, duration provided by GBD 
studies for epilepsy and chart reviews data for severe headache was used. Chart reviews 
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captured information on duration of NCC-associated severe headache from the time of 
diagnosis to the date when data was abstracted. Mean duration of NCC-associated severe 
headache was calculated from those data for each age group. Due to lack of information 
on duration of severe headache for the 0-14 years age group, duration used for the 15-44 
years age group was used for both groups. Mean durations of the clinical manifestations 
used in this study are listed in Tables 4 and 5.  
 
 
Table 4: Age and sex specific mean duration of epilepsy in years. 
Parameter Mean* 
(years) 
References 
Mean duration of disability in males between 0 and 4 years of 
age 
0.82 [75] 
Mean duration of disability in males between 5 and 14 years of 
age 
2.64 [75] 
Mean duration of disability in males between 15 and 44 years of 
age 
5.14 [75] 
Mean duration of disability in males between 45 and 59 years of 
age 
2.33 [75] 
Mean duration of disability in males older than 60 years of age 1.16 [75] 
Mean duration of disability in females between 0 and 4 years of 
age 
1.27 [75] 
Mean duration of disability in females between 5 and 14 years of 
age 
3.41 [75] 
Mean duration of disability in females between 15 and 44 years 
of age 
6.83 [75] 
Mean duration of disability in females between 45 and 59 years 
of age 
6.73 [75] 
Mean duration of disability in females older than 60 years of age 3.5 [75] 
*Distribution: fixed. 
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Table 5: Age and sex specific mean duration of migraine/severe headaches in years. 
 
Parameter Mean* 
(years) 
References 
Mean duration of disability in males and females 
between 0 and 4 years of age 
4.28 Chart reviews 
Mean duration of disability in males and females 
between 5 and 14 years of age 
4.28 Chart reviews 
Mean duration of disability in males and females 
between 15 and 44 years of age 
4.28 Chart reviews 
Mean duration of disability in males and females 
between 45 and 59 years of age 
2.90 Chart reviews 
Mean duration of disability in males and females 
older than 60 years of age 
4.75 Chart reviews 
*Distribution: fixed. 
 
 
Literature search strategy for prevalence of epilepsy in Mexico 
The available literature was reviewed to estimate the prevalence of epilepsy in 
Mexico [76,77]. Those studies that used advanced imaging, standardized previously 
validated questionnaires, door to door surveys and/or interviews with parents for data 
collection were included. The adult epilepsy prevalence estimates used in this study were 
based on epilepsy incidence and prevalence estimates for Mexico found in a systematic 
review of the literature on epilepsy frequency for Latin America [76]. This review 
reported prevalence estimates for Tepatitlan, Jalisco, Mexico and a representative 
subsample living in urban areas of Mexico during the first National Survey on Drug 
Abuse. Therefore, we took the mean of the two available prevalence estimates for adult 
males (0.83% and 3.4%) and females (0.55% and 4.8%) and modeled the uncertainty 
with a triangular distribution. For the prevalence of epilepsy in children, an estimate 
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from nine year old children was used [77]. This study reported minimum, maximum and 
mean values of epilepsy prevalence in 9 year old Mexican school children from Tlalpan, 
Mexico. Therefore, we modeled the uncertainty with a triangular distribution. Due to the 
absence of data for children of other ages, this estimate was used for the entire 0-14 year 
age group. The epidemiological parameters used to calculate DALYs lost due to NCC in 
Mexico are provided in Table 6. 
 
 
Table 6: Epidemiological parameters used to calculate DALYs associated with 
NCC in Mexico. 
 
Parameter Value 
 
95%CI Distribution Reference 
2005 Population of Mexico (‘000) 105,329  Fixed [79] 
Mortality due to epilepsy in Mexico 1500  Fixed [74] 
 Prevalence of epilepsy in 0-14 year old 
males and females in Mexico (%)  
4.2 2.2 – 4.3 Triangular 
(1.8, 4.2, 4.4) 
[77] 
Prevalence of epilepsy in males older 
than 15 years of age in Mexico (%)   
2.15 1.1 – 3.1 Triangular 
(0.83,2.1,3.4) 
[76] 
Prevalence of epilepsy in females older 
than 15 years of age in Mexico (%) 
2.7 1.0 – 4.3 Triangular 
(0.55,2.6,4.8) 
[76] 
Proportion of epilepsy associated with 
NCC in individuals 0-14 years of age in 
Mexico   
0.22 0.18 - 0.26 Uniform 
(0.18,0.26) 
[13,80] 
Proportion of epilepsy associated with 
NCC in individuals older than 15 years 
of age in Mexico 
0.23 0.18-0.29 Uniform 
(0.18,0.29) 
[13,80] 
Proportion of epilepsy in  people with 
NCC (all age groups combined) 
0.58 0.14 – 
0.96 
Normal 
(0.58,0.22) 
[81] 
Proportion of individuals with severe 
headache presenting  with NCC 
0.22 0.16 – 
0.29 
Normal 
(0.22, 0.03302) 
[81,82] 
Proportion of epilepsy patients 
receiving treatment 
0.45 0.4-0.5 Uniform 
(0.4,0.5) 
[75,83] 
Proportion of severe headache patients 
receiving treatment 
0.60 0.525-0.69 Uniform 
(0.525,0.69) 
[84,85] 
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Estimation of the number of NCC cases with epilepsy in Mexico  
 
The number of cases of epilepsy in Mexico was estimated by multiplying the size 
of the population of Mexico in 2005 [79] by the prevalence of epilepsy in Mexico 
reported in Burneo et al., (2005) for adults and Garcia-a-Pedroza et al., (1983) for 
children [76,77]. The 2005 population of Mexico was chosen because age and sex 
stratified data for Mexico could only be found up to this year. In addition, the GBD 2010 
Study will use 2005 estimates. In a recent meta-analysis of the literature, it was 
estimated that 29% of adults and 26% of children 0-19 years of age with epilepsy had 
NCC lesions in endemic areas [13]. However, since all regions of Mexico are not 
equally endemic for NCC, an estimate from urban areas of India was assumed to be 
similar to urban areas of Mexico. Therefore, the estimate from urban areas of India was 
used as the lower bounds and meta-analysis data was used as the upper bounds, with 
uncertainty modeled with a uniform distribution. Hence, the numbers of adults and 
children with epilepsy in Mexico were multiplied by the respective proportion of people 
with epilepsy (PWE) with NCC lesions to obtain the number of NCC-associated cases of 
epilepsy in adults and children in Mexico. The 1996 GBD Study estimated that 40% of 
total epilepsy cases receive treatment in Mexico [75] and Meyer et al., (2009) estimated 
that 50% of total epilepsy cases receive treatment in lower middle- and upper middle- 
income countries [83].  Therefore, the proportion of NCC-associated epilepsy cases 
receiving treatment was estimated by multiplying the number of NCC-associated 
epilepsy cases in Mexico by the percentage seeking treatment, modeling the uncertainty 
with a uniform distribution with 40% as the lower bounds and 50% as the upper bounds. 
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A flowchart depicting how incidence of NCC-associated epilepsy in Mexico was 
determined is shown in Figure 4.  
 
 
 
Figure 4: Flowchart for estimating the incidence of NCC-associated epilepsy in 
Mexico (for adults).  
 
Note: The flowchart provides the mean values of the model parameters. Please refer to Table 6 for 
information concerning distributions applied to the various parameters. 
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Mexico epilepsy cases 
NCC-associated 
epilepsy in 
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Treated NCC-
associated 
epilepsy 
Untreated NCC-
associated 
epilepsy 
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NCC-associated 
epilepsy 
Incidence of 
untreated NCC-
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2.15% 
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45% 
55% 
Divided by duration 
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Estimation of the number of NCC cases with severe headache in Mexico 
 A recent meta-analysis of the literature indicated that approximately 58% and 
22% of symptomatic NCC cases seen in neurological clinics  have epilepsy and severe 
headaches as a clinical manifestation, respectively [81]. Therefore, we assumed that 58% 
of NCC cases who are seen at neurology clinics in Mexico is equivalent to the number of 
NCC-associated epilepsy cases in Mexico who receive treatment (45% of total NCC-
associated epilepsy cases). The total number of clinical cases of NCC was calculated by 
dividing the number of NCC-associated epilepsy cases who go to neurology clinics by 
58%. The number of people in Mexico with NCC-associated severe headache who go to 
neurology clinics was calculated by multiplying the total number of NCC cases who go 
to neurology clinics by the proportion of NCC cases in neurology clinics who have 
severe headache as a clinical manifestation. Morillo et al. (2005) estimated that 52.5% of 
total migraine cases receive treatment in Mexico [84] and Lipton et al. (2002) estimated 
that 69% of total migraine cases receive treatment in the USA [85]. The estimate from 
the USA was considered the maximum proportion of severe headache cases that receive 
treatment in Mexico and the Mexican value considered the minimum value, with 
uncertainty modeled using a uniform distribution. Therefore, the total number of people 
with NCC-associated severe headache was calculated by dividing the total number of 
NCC cases presenting to neurology clinics with severe headache by these values. A 
flowchart depicting how incidence of NCC-associated severe headache in Mexico was 
determined is shown in Figure 5. 
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Figure 5: Flowchart for estimating the incidence of NCC-associated severe 
headache in Mexico. 
 
Note: The flowchart provides the mean values of the model parameters. Please refer to Table 6 for 
information concerning distributions applied to the various parameters. 
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Analysis 
A spreadsheet model using @Risk software (Palisade Corporation, Ithaca, NY, 
version 4.5) was used to estimate the number of DALYs lost due to NCC. Monte Carlo 
methods were employed to simulate the data and to calculate 95% credibility intervals. 
The model was run for 20,000 iterations. Different distributions were used according to 
the type of information available for each of the included parameters. In addition, 
regression sensitivity analysis was performed to identify which parameter had the 
greatest effect on the total DALYs estimate. 
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4. RESULTS 
 
 
 
4.1 Patients descriptive data from chart reviews 
 
Chart reviews were conducted for 101 patients from the IMSS and 177 patients 
from the INNN. There were slightly more female patients (144) than male patients (134). 
Patient ages ranged from 19-88 years, with a mean of 47 years and a median of 46 years 
(Figure 6).  
 
 
 
Figure 6: Age distribution of NCC patients presenting to the INNN and the IMSS.  
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Most of the patients (82%) attending the IMSS were from Ciudad de Mexico 
(Mexico DF (Distrito Federal)). Patients attending the INNN were primarily from Estado 
de Mexico (37%) and Mexico DF (26%) (Figure 7). 
 
 
 
 
Figure 7: Distribution of patients according to their state of residence (number of 
patients attending the IMSS = 101, number of patients attending the INNN = 177). 
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4.2 Clinical manifestations associated with NCC cases 
 
NCC (in and out) patients reported numerous clinical manifestations throughout 
the course of disease (Table 7 and Figure 8), with severe headache being the most 
common. In some patients, more than one symptom was present such as epilepsy and 
severe headache; epilepsy, hydrocephalus and severe headache; hydrocephalus and 
epilepsy. The most common combination was hydrocephalus and severe headache (15%) 
(Table 8). Of the cases evaluated in this study, 50% had a long clinical history of NCC 
(diagnosed 6 or more years prior to the date of the patient’s last appointment at the 
neurology clinic).  
 
 
Table 7: NCC related manifestations of patients seeking treatment at the INNN or 
IMSS (n=278). 
 
Symptoms Number Proportion 
Severe headaches 132 0.48 
Hydrocephalus 131 0.47 
Epilepsy 87 0.31 
Increased intracranial pressure 34 0.12 
Acute symptomatic seizures 20 0.07 
Single seizures 7 0.03 
Vasculitis 5 0.02 
Stroke 3 0.01 
Dementia 2 0.01 
Note: The percentages sum to more than 100% because patients could present with more than one 
symptom. 
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H = Hydrocephalus, SH = Severe headache, E = Epilepsy, SS = Single seizure, ASS = 
Acute symptomatic seizures, IIP= Increased intracranial pressure, D = Dementia, V = 
Vasculitis, S = Stroke  
 
Figure 8: NCC related clinical manifestations of patients seeking treatment at the 
INNN or the IMSS. 
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Table 8: Different combinations of clinical manifestations in NCC patients seeking 
treatment at the INNN or the IMSS (n=278).  
 
Combinations Number Proportion 
Epilepsy and hydrocephalus 18 0.06 
Severe headache and hydrocephalus  43 0.15 
Severe headache, hydrocephalus and epilepsy  12 0.04 
Epilepsy and severe headache  26 0.09 
Increased intracranial pressure and hydrocephalus  19 0.07 
Increased intracranial pressure and severe headache  26 0.09 
Increased intracranial pressure, severe headache and 
hydrocephalus  
13 0.05 
Epilepsy alone 52 0.19 
Acute symptomatic seizures alone 9 0.03 
Single seizure alone 3 0.01 
Hydrocephalus alone 26 0.09 
Severe headache alone 33 0.12 
Increased intracranial hypertension alone 2 0.007 
 
 
4.3. Socio-demographic characteristics of NCC cases 
Of the 278 NCC cases whose medical charts were reviewed, 224 (80.6%) were 
outpatients who consented to be interviewed.  Of these, 101 sought treatment at the 
IMSS and 123 sought treatment at the INNN. Of the total interviewed NCC patients, 
71.4% were pork consumers, while 28.6% never ate pork.  Of those who ate pork, 53.0% 
reported only eating well done pork while 16.0% reported consuming undercooked pork. 
Only three (1.3%) patients currently owned pigs whereas 51% had owned pigs one to 
five years prior. Present pig owners lived in Puebla, Acapulco and Edo, Mexico. A total 
of 20% of present or former pig owners had a history of seeing cysts in their pigs. Of the 
interviewed NCC patients, 24.0% had a history of seeing tapeworms in their feces and 
9.0% of patients’ near relatives were known tapeworm carriers (Table 9). 
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Table 9: Pig ownership and taeniasis history among NCC patients (n = 224). 
 
 IMMS INNN Total Proportion  
Currently or previously owned pigs 51 67 118 0.52 
Currently or previously ate pork  65 95 160 0.71 
Ate undercooked pork 6 20 26 0.16 
Had a history of taeniasis  36 18 54 0.24 
Relative of a known tapeworm carrier 13 8 21 0.09 
 
 
Only two (0.9%) NCC patients did not currently have a toilet in their home and 
always defecated outdoors, while 11 (5.0%) sometimes defecated outdoors. In addition, 
70.9% of the patients drank bottled water and 12.9% drank water from a well. Of the 
total NCC patients interviewed, 28.6% were unaware of cysts occurring in pigs. Among 
160 patients who had heard about cysts, 75.6% did not know how pigs acquired the 
cysts. Similarly, 25.0% of patients did not know about tapeworm infections in humans. 
Among people who did know about human tapeworms, 57.1% were not aware of how 
the worms were transmitted to humans (Table 10). Of those patients who knew about 
tapeworms, 28.3% of patients got their information from physicians and the remainder 
obtained their information from radio/newspaper, friends/families or a traditional healer. 
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Table 10: Hygienic behavior and knowledge of T. solium transmission (n = 224). 
 
 IMMS INNN Total Proportion  
Did not have a toilet in their homes and 
defecated outdoors 
0 2 2 0.01 
Did not know about cysts in pigs 36 28 64 0.29 
Knew about the cysts, but did not know 
about transmission  
47 73 121 0.76 
Did not know about the tapeworm in 
humans 
12 44 56 0.25 
Knew about the tapeworm, but did not 
know about transmission to humans 
62 34 96 0.57 
 
 
4.4. Measurement of outcome (quality of life)  
 Of the 278 NCC patients whose medical charts were reviewed, 224 (80.6%) were 
outpatients who consented to complete the SF-12 v2 quality of life survey. Four pairs of 
cases and controls were not used for the analysis due to missing data.  
 The Shapiro-Wilk test indicated that the SF-12 v2 data were not normally 
distributed. Therefore, health scores for NCC patients and the comparison group were 
compared using the Man-Whitney test. Individuals with NCC had a significantly lower 
score for all eight domains of health (physical functioning, role physical, bodily pain, 
vitality, general health, social functioning, role emotional and mental health) compared 
with the age and sex matched population (p < 0.05) (number of cases and controls pairs 
= 220) (Figure 9).  
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 PF = Physical functioning, RP = Role physical, BP = Bodily pain, GH= General health 
V = Vitality, SF = Social functioning, RE= Role emotional, MH= Mental Health. 
 
Figure 9: Health scores from the SF-12 v2 health survey for NCC patients versus 
their matched control group (Overall population). 
Note: Dot in the box plot represents the mean of the health scores. 
 
 
Male NCC outpatients had significantly lower scores in role physical, social 
functioning, role emotional and mental health compared with their matched controls 
from the same source population (p<0.05) (n=104 pairs) (Figure 10).  
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Figure 10: Health scores from the SF-12 v2 health survey for NCC patients versus 
their matched control group (Males). 
Note: Dot in the box plot represents the mean of the health scores. 
 
 
Except for general health, female NCC outpatients had significantly lower scores 
in all domains compared with their matched controls (p<0.05) (n=116 pairs) (Figure 11).  
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Figure 11: Health scores from the SF-12 v2 health survey for NCC patients versus 
their matched control group (Females). 
Note: Dot in the box plot represents the mean of the health scores. 
 
 
To assess the possible effect modification of age on the difference in scores, a 
stratified analysis was conducted using an age cut off of 45 years old. Forty-five years 
was chosen since the median age of the NCC cases was 46 years.  Younger individuals 
(< 45 years of age) with NCC had lower health scores in all eight domains compared to 
their matched controls (n=100 pairs) (Figure 12). However, for the older individuals 
(>45 years of age), four domains (physical functioning, bodily pain, general health and 
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vitality) were not significantly different between the two groups (n=120 pairs) (Figure 
13).  
 
 
 
 
Figure 12: Health scores from the SF-12 v2 health survey for NCC patients versus 
their matched controls (Younger (<=45 years) group). 
Note: Dot in the box plot represents the mean of the health scores. 
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Figure 13: Health scores from the SF-12 v2 health survey for NCC patients versus 
their matched controls (Older (>45 years) group). 
Note: Dot in the box plot represents the mean of the health scores. 
 
 
 
Similarly, the comparison between the NCC cases and their matched controls 
was stratified by the time since diagnosis. A cut-off point of five years was chosen as the 
cutoff since the median time since diagnosis of the NCC outpatients was 5 years.  
Thirty-six cases did not have time of diagnosis documented in their medical charts and 
were, therefore, not included in this comparison. NCC cases diagnosed less than 6 years 
ago had lower health scores in all eight domains compared with their matched controls 
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(n=102 pairs) (Figure 14). However, three domains (bodily pain, general health and 
vitality) were not significantly different for NCC cases diagnosed more than six years 
ago and their matched controls (n=82 pairs) (Figure 15).  
 
 
 
Figure 14: Health scores from the SF-12 v2 health survey for NCC patients versus 
their matched controls (Diagnosed less than 6 years ago). 
Note: Dot in the box plot represents the mean of the health scores. 
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Figure 15: Health scores from the SF-12 v2 health survey for NCC patients versus 
their matched controls (Diagnosed 6 or more years prior). 
Note: Dot in the box plot represents the mean of the health scores. 
 
 
The comparison between the NCC cases and their matched controls was also 
stratified by symptoms. Except for physical functioning and bodily pain, NCC-
associated epilepsy outpatients had significantly lower scores in all domains compared to 
their matched controls (p<0.05 pairs) (n=63) (Figure 16). 
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Figure 16: Health scores from the SF-12 v2 health survey for NCC patients versus 
their matched controls (Epilepsy group). 
Note: Dot in the box plot represents the mean of the health scores. 
 
 
Except for general health, NCC-associated severe headache outpatients had 
significantly lower scores in all domains compared to their matched controls (p<0.05) 
(n=100 pairs) (Figure 17). 
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Figure 17: Health scores from the SF-12 v2 health survey for NCC patients versus 
their matched controls (Severe headache group). 
Note: Dot in the box plot represents the mean of the health scores. 
 
 
Physical and Mental Component Summary scores 
 From the results of norm based Physical and Mental Component Summary 
scores, calculated using U.S. norm factor score coefficients, both summary scores for 
NCC cases were lower than that of the U.S. norms. In norm based scoring, values are 
considered lower than the comparison group if the value is less than 50. Physical and 
mental component summary scores for different sub groups are shown in Table 11. 
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Table 11: Physical Component Summary (PCS) and Mental Component Summary 
(MCS) scores for different sub groups compared to U.S. norms. 
 
 PCS MCS 
Mean  Median Mean Median 
All  NCC patients 45.9 47.7 45.8 47.2 
Male NCC patients 46.1 48.2 47.2 47.7 
Female NCC patients 45.7 48.2 44.7 47.7 
Younger (<45 years) NCC 
patients 
47.8 48.8 42.9 43.5 
Older (>= 45 years) NCC 
patients 
44.4 45.7 48.2 50.1 
NCC-associated epilepsy 
patients 
46.4 47.2 43.2 42.1 
NCC-associated severe headache 
patients 
45.8 47.7 46.7 47.7 
Diagnosed less than 6 years ago 45.3 47.6 45.4 47.3 
Diagnosed 6 or more years ago  45.8 46.8 45.7 45.9 
Controls 48.5 50.5 51.8 52.6 
 
 
4.5. Non-monetary burden of NCC in Mexico 
Prevalence and annual incidence cases of NCC-associated epilepsy and severe 
headache in Mexico 
 Approximately 0.7% of the total population of Mexico was estimated to have 
NCC-associated epilepsy and 0.2% was estimated to have NCC-associated severe 
headaches. The estimated numbers of people in Mexico with NCC-associated epilepsy 
and NCC-associated severe headaches are given in Table 12. 
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Table 12: Estimated number of people with NCC-associated epilepsy and severe 
headaches in Mexico.  
 
 Mean Median 95% CR 
People in Mexico with NCC-associated 
epilepsy  
740,404 739,854 574, 207 – 903,967 
People in Mexico with NCC-associated 
severe headache 
209,337 207,592 151,608– 276,947 
  
 
 Percentages of annual incident cases of NCC that are associated with epilepsy 
and severe headache were 0.3 and 0.05, respectively. The mean estimated number of 
annual incident cases of NCC-associated epilepsy and severe headaches and their 95% 
credibility region are provided in Table 13.  
 
 
Table 13: Estimated annual incidence cases of NCC-associated epilepsy and severe 
headache in Mexico. 
 
 Mean Median 95% CR 
Annual number of incident cases of 
NCC-associated epilepsy 
268,496 269,057 224,122 – 310,531 
Annual number of incident cases of 
NCC-associated severe headaches 
51,055 50,655 37,072 – 67,398 
 
 
DALYs due to NCC-associated epilepsy and severe headaches in Mexico. 
 The total number of DALYs lost due to NCC in Mexico was estimated to be 
99,866 (95% CR: 43,187 – 189,182), with a mean of 0.95 (95% CR: 0.4 – 1.8) DALY 
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lost per thousand persons per year. Estimated numbers of DALYs lost due to epilepsy 
and severe headaches are given in Table 14. 
 
 
Table 14: Estimated annual number of DALYs lost due to NCC-associated epilepsy 
and severe headache in Mexico. 
 
Source of 
DALYs 
Mean Median 95%CR Percentage of 
total DALYs 
DALYs due to 
epilepsy 
96,450 90,408 40,012 – 185,223 96 
DALYs due to 
severe headache 
3,416 3,341 2,155 – 5,047 4 
Total  99,866 93,824 43,187 – 189,182 100 
  
 
 Thirteen percent of DALYs lost due to NCC was attributed to YLL and the 
remaining 87% was due to YLD. Estimated number of YLL and YLD due to NCC in 
Mexico are shown in Table 15. 
 
 
Table 15: Estimated annual number of YLL and YLD associated with NCC-
associated epilepsy and severe headache in Mexico. 
 
Source of 
DALYs 
Mean Median 95%CR Percentage of 
total DALYs 
YLL 12,252 12,322 10,329 – 13,938 13 
YLD 87,614 81,583 31,061 – 176,586 87 
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Number of DALYs lost in different age groups 
 The estimated number of DALYs lost was highest in the 15-44 year age group 
and lowest in those greater than 60 years of age. The numbers of DALYs lost for males 
and females were similar for all age groups. The distributions of DALYs lost for males 
and females in different age groups are shown in Figure 18. 
 
 
 
Figure 18: Estimated mean number of DALYs lost due to NCC for males and 
females in different age groups in Mexico. 
 
 
Uncertainty analysis 
 The epilepsy disability weight for untreated people older than 5 years of age, the 
epilepsy disability weight for treated people older than 5 years of age and the total 
number of NCC patients who go to neurology clinics were the three parameters with the 
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greatest effect on the total DALYs estimate. Parameters which had the greatest effect on 
the number of DALYs lost due to NCC in Mexico are shown in Figure 19. 
 
 
Figure 19: Sensitivity analysis of the total NCC-associated DALYs estimate for 
Mexico. 
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5. DISCUSSION 
 
 
 
Neurocysticercosis (NCC) is a public health problem in Latin America and 
developing countries of Asia and Africa [6]. Prevalence of NCC in endemic areas of 
Mexico, including asymptomatic cases, was found to be as high as 10.8% by computed 
tomography in certain villages [56,58]. In our study, most patients were from the vicinity 
of Mexico City suggesting that people from the endemic regions may not commonly 
travel to referral hospitals or that NCC cases moved closer to the hospital following their 
diagnosis. Therefore, the numbers of patients treated in neurology referral hospitals most 
likely only represent a fraction of the total regional population with NCC, with less 
severe cases remaining unreported or treated in regional hospitals. 
 
5.1 NCC-associated clinical manifestations 
Clinical manifestations associated with NCC were found to be pleomorphic. 
Manifestations can be neurologic as well as psychiatric and include severe headache, 
epilepsy, seizures, stroke, dementia, and depression [3,41]. This variability is related to 
the number and location of lesions as well as the extent of the host’s immune response to 
the parasites [4]. In this study, severe headache was the most common clinical 
manifestation presented by NCC patients in two neurological hospitals in Mexico City. 
This conclusion differs somewhat from other available literature. For example, a recent 
systematic review found that epilepsy was the most common clinical manifestation of 
NCC (58%) followed by severe headache (22%) in neurology clinics in endemic regions. 
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[81]. However, distribution of clinical manifestations at the community level is 
unknown. 
 
5.2 NCC socio-demographic characteristics 
 Humans are exposed to eggs of T. solium by autoinfection, by direct contact with 
another tapeworm carrier, or indirectly by ingestion of food or water contaminated with 
infected human feces. In this study, 24% of surveyed patients had a history of 
tapeworms in their feces, indicating that they may have acquired NCC through 
autoinfection. Others might have acquired the disease from their taeniasis carrier 
relatives, with 9.0% of patients indicating that they had a relative with taeniasis. 
However, reports of taeniasis were self reported and therefore, the tapeworms could 
have been T. saginata instead of T. solium. 
According to the information obtained from this study’s questionnaires, 1% of 
patients reported that they did not currently have a toilet in their home. In some rural 
areas, even though people have toilets in their homes, they are built in such a way that 
pigs have direct access to human excrement [86]. Easy access of swine to human feces 
helps to complete the life cycle of T. solium and increase the risk of disease transmission 
in Mexico. Most of the patients in this study did not know about T. solium in pigs or 
humans and were unaware of the parasite’s life cycle. These people were diagnosed with 
NCC and should be educated about the condition as well as its mode of transmission. 
While the medical profession is one of the best sources of disease information, it appears 
that physicians do not always adequately discuss the transmission of T. solium with their 
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patients. Although 59.7% of patients knew about the tapeworm, only 28.3% of these 
individuals acquired this information from a physician.  Physicians should realize that 
they are not only responsible for treating their patients, but also for providing 
information about the disease and its mode of transmission. Findings from this study 
indicate that people in endemic areas of Mexico need better education about the disease 
and its mode of transmission. Therefore, it is important to find effective methods of 
providing information to the public to correct this deficit in knowledge. 
 
5.3 Quality of life survey 
 The SF-12 v2 health survey was chosen to evaluate quality of life of NCC 
patients compared to an age and sex matched control population due to its brevity and 
ease of use. Other studies have used this health survey to show a reduction in quality of 
life due to echinococcosis and migraine [66,67,87]. However, no previous study has 
compared quality of life of NCC patients with a control population. 
 When the overall study population was considered, NCC patients scored 
significantly lower in all eight domains of health compared to controls. In addition, the 
PCS and MCS were also low compared to the U.S. norms.  Findings from this study 
suggest that NCC not only affects the physical health, but also the mental health of 
patients. Different clinical manifestations associated with NCC may lead to deteriorated 
quality of life and, therefore, lower health scores. Various studies have shown that 
clinical manifestations such as epilepsy, stroke, and migraine reduced the quality of life 
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of individuals using the SF-12, the Comprehensive Quality of life Scale and the EuroQol 
Group Index [87,88,89]. 
 This study showed that males with NCC had significantly lower scores in role 
physical, social functioning, role emotional and mental health. From these findings, it 
appeared that males were more impaired in mental domains. However, the MCS and 
PCS were found to be equally lower when compared to US norms. In female patients, all 
domains, except for general health, were significantly lower compared to an age 
matched control population. PCS and MCS scores of females compared to U.S. norms 
were found to be equally affected suggesting that women affected with NCC are 
impaired similarly in the mental and physical domains. PCS and MCS were low in 
females compared to males, which suggests that females with NCC are more impaired 
mentally as well as physically. 
This study also compared the quality of life of NCC patients by separating the 
entire group by age (i.e., younger (≤ 45 years old) versus older (>45 years old)). 
Younger individuals had significantly lower health scores in all eight domains compared 
with an age and sex matched control population. MCS scores were more affected than 
PCS scores when compared to U.S. norms.  PCS and MCS scores verified that younger 
individuals with NCC are more affected mentally.  However, in the older group, four 
domains were not significantly different from the sex and age matched control 
population.  Those domains which were different also did not vary greatly in their actual 
values. This may be due to the general population of older individuals already having a 
lower quality of life due to other conditions or circumstances. Mean time since diagnosis 
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of NCC patients was similar in both the younger and older categories (5.7 and 4.9 years, 
respectively) suggesting that this difference is not due to acclimatization to their 
conditions due to the long duration of disease. From norm based summary scores 
findings, older individuals were more affected physically when compared to U.S. norms.  
This study compared the quality of life of those patients who had epilepsy and 
severe headache as a clinical manifestation separately to the age and sex matched control 
population. NCC-associated epilepsy outpatients scored significantly lower in all 
domains except physical functioning and bodily pain. The mean MCS score (43.2) was 
lower than the mean PCS score (46.4). These findings suggest that NCC patients with 
epilepsy are more affected in the mental domains. However, NCC-associated severe 
headache patients were significantly lower in all domains except general health 
compared to the control population. Their MCS and PCS scores also indicated that they 
were affected similarly in mental and physical health domains. The mean MCS score of 
NCC-associated severe headache patients (46.7) was low compared to that of NCC-
associated epilepsy patients (43.2) indicating that NCC patients with epilepsy were more 
affected mentally than NCC patients with severe headache.  
Those individuals who were diagnosed more than 6 years ago did not score 
significantly different in bodily pain, general health and vitality compared to the age and 
sex matched control population. However, those individuals who were diagnosed less 
than 6 years ago were significantly different in all eight domains. This may suggest that 
individuals who were diagnosed longer ago have somewhat acclimated to their situation 
or that their quality of life has improved due to the treatment they received. However, 
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PCS and MCS scores were similar in both individuals who were diagnosed less than 6 
years ago and more than 6 years ago compared to general U.S. norms suggesting that the 
mental and physical health states are not associated with the time since diagnosis. 
 When we compared our findings with another study conducted for people with 
severe mental illness in the U.S., the mean PCS scores for NCC-associated epilepsy and 
severe headache (46.4 and 45.8, respectively) were found to be similar to the bipolar 
group (46.1). However, the mean MCS scores for NCC-associated epilepsy and severe 
headache (43.2 and 46.7, respectively) were higher compared to the bipolar group (39.6).  
The mean MCS score for NCC-associated epilepsy was similar to schizophrenia (42.4) 
whereas the mean PCS score was higher for schizophrenia (48.2).  On the other hand, 
the mean MCS score for NCC-associated severe headache was higher and the mean PCS 
score was  lower compared to schizophrenia.[90] However, these comparisons need to 
be made with care since the mental illness study was based on the U.S. population and 
not on the Mexican population. In addition, U.S. norms were used to calculate the PCS 
and MCS for Mexican NCC patients, which may not be optimal if Mexican and U.S. 
norms are found to differ substantially. 
 In order to get an idea of how well the U.S. norms fit the control group, PCS and 
MCS score for controls were compared to the U.S. norms. The mean PCS score for 
controls (48.5) was lower compared to U.S. norms whereas the mean MCS score for 
controls (51.8) was higher suggesting that PCS score for Mexican NCC patients might 
be overestimated and MCS scores for Mexican NCC patients might be underestimated.  
 69 
 
 In order to limit information bias in this study, the Mexican Spanish version of 
the SF-12 v2 was administered to NCC patients by a native Spanish speaking 
interviewer. However, persons administering the questionnaire were not blinded, which 
may have resulted in information bias. Similarly, to avoid age as a confounder, controls 
were matched and were selected from individuals who accompanied non-related patients 
and could be paired with an NCC patient by sex and age (± 5 years). However, the 
controls were taken from hospitals and might not represent the general population of 
Mexico. In order to calculate the PCS and MCS summary scores, factor score 
coefficients for the U.S. were used due to lack of information specific to the Mexican 
population. However, using U.S. norms provides a basis of uniformity for cross-national 
comparisons. This study was also hospital-based, with all NCC patients sampled 
clinically affected.  This will most likely overestimate the overall difference between 
health domains of NCC patients and the age and sex matched control population. 
 
5.4 Non-monetary burden of NCC in Mexico 
 This study represents the second study to estimate the burden of NCC using 
DALYs. The first study, which was conducted in Cameroon, estimated the burden of T. 
solium cysticercosis by calculating human non-monetary burden of disease and both 
human and animal-associated monetary disease burden  [9]. The Cameroon study 
estimated human NCC burden based on epilepsy alone and used serology to diagnose 
NCC which has been shown to have poor performance in detecting cases. However, the 
estimated number of DALYs lost per thousand persons per year was higher in Cameroon 
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compared to Mexico, since NCC is more prevalent in Cameroon than in Mexico. 
Although the estimated mean number of DALYs lost per thousand persons per year is 
higher in Cameroon, the number of NCC-associated epilepsy cases is higher in Mexico 
compared to Cameroon. This occurs because of the difference in the percentage of NCC 
patients that receive treatment, with people in Mexico estimated to be four times more 
likely to receive treatment for epilepsy than people in Cameroon, and the difference in 
the population size of the two countries [75]. 
 According to 2004 GBD estimates, 1.7 DALYs per thousand persons per year 
were estimated to be lost due to epilepsy in Mexico, with approximately the same 
number of DALYs lost due to migraine. Estimated DALYs lost per thousand persons per 
year for other parasitic diseases in Mexico include ascariasis: 0.05, trichuriasis: 0.10 and 
hookworm: 0.03 [74]. Compared to these parasitic diseases, DALY estimates for NCC 
were much higher because NCC not only causes morbidity but also mortality in humans. 
However, when estimates from the 2004 GBD Study are compared with other 
independent studies, estimates from the GBD Study tend to be lower. For example, a 
study conducted in Cameroon estimated 9 DALYs lost per thousand persons per year 
due to NCC-associated epilepsy [9]. However, according to the 2004 GBD estimate, 
only 2.45 DALYs per thousand persons per year were lost due to all cases of epilepsy in 
Cameroon [74]. This suggests that the GBD Study estimates were most likely 
underestimates. However, the Cameroon study also has to be interpreted with care since 
it used serology as a diagnostic method and could have potentially overestimated the 
number of NCC-associated epilepsy cases at the country level. 
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Numerous studies have tried to evaluate the prevalence of NCC in endemic 
regions of Mexico [20,56,57,58]. However, none of them have attempted to assess the 
socio-economic burden of NCC. This study was the first to report an estimate of the non-
monetary burden of clinical NCC in Mexico. DALY estimates only incorporate human 
health losses. However, NCC not only causes losses to human health, but also to the 
local swine industry. Therefore, NCC causes socio-economic losses which are not 
accounted for by DALYs. Hence, the total societal burden is higher than that estimated 
by the number of DALYs lost. Therefore, the monetary burden of T. solium in Mexico is 
currently being estimated as part of a larger project, with the data to be presented in a 
later publication.  
 Morbidity of NCC is high compared to mortality [91]. Most of the clinical 
manifestations associated with NCC cause disability rather than death. The NCC-
associated DALYs estimate for Mexico only included two clinical manifestations 
(severe headache and epilepsy). There were no publications reporting NCC-associated 
severe headache mortality. Therefore, YLL was calculated using only one clinical 
manifestation of NCC (epilepsy). This is likely the reason why our study has high YLD 
and low YLL estimates. A similar study conducted in Cameroon also showed high YLD 
and low YLL due to NCC-associated epilepsy [9]. 
Results from this study showed that DALYs lost due to NCC were highest in the 
15-44 year age group. Sensitivity analysis results indicated that DALY estimates were 
mostly affected by disability weights for treated and untreated people who were older 
than 5 years of age. The number of cases of NCC associated headache and epilepsy were 
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also highest in the 15-44 year age group, which is similar to other published studies 
which showed that the peak age of incidence of NCC is in middle aged groups [92]. 
Therefore, NCC appears to affect those people who are often considered by society to be 
the most productive.  
Since disability weights for NCC were not included in the original GBD studies, 
it was necessary to use disability weights and duration of clinical manifestations 
associated with NCC. However, all clinical manifestations (e.g., hydrocephalus, 
increased intracranial pressure) associated with NCC do not have GBD disability 
weights.  Therefore, further studies are needed to evaluate the disability weights 
associated with all clinical manifestations associated with NCC. 
 This study has some limitations. The total estimated number of DALYs lost is 
most likely underestimated since only the NCC clinical manifestations of epilepsy and 
severe headache were included. Other symptoms such as stroke and dementia have not 
been taken into account because very little information is available about these clinical 
manifestations. Due to the lack of information on NCC-associated severe headache and 
epilepsy in the original GBD Study, disability weights or epilepsy and migraine were 
used, with migraine a surrogate for severe headaches. Similarly, information about 
incidence of epilepsy and severe headaches was not available. Therefore, number of 
incident cases was calculated using prevalence and overall duration estimates for 
epilepsy and severe headaches. As the duration of these conditions is not case specific, 
estimates may lack precision. In addition, mean duration of NCC-associated severe 
headache was calculated from chart reviews data. This will underestimate the duration 
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and therefore overestimate the incidence of NCC-associated severe headache. Due to 
limited country specific data, parameters used for calculating the proportion of NCC 
patients with epilepsy and the proportion of NCC patients with severe headaches were 
based on a systemic review of the NCC literature [13,81]. Therefore, additional studies 
are needed to obtain precise estimates of the socioeconomic impact of NCC in Mexico. 
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6. SUMMARY AND CONCLUSIONS 
 
 
 
 NCC continues to be a public health problem in Mexico, with an estimated 0.95 
(95%CR: 0.4 – 1.8) DALYs lost per thousand persons per year. NCC produces a variety 
of clinical manifestations such as severe headache, epilepsy, hydrocephalus, stroke and 
other neurological symptoms. Severe headaches, epilepsy and hydrocephalus were the 
most common clinical manifestations reported in this study.  
 Individuals with NCC had a significantly lower score for all eight domains of 
health (physical functioning, role physical, bodily pain, vitality, general health, social 
functioning, role emotional and mental health) measured by the SF-12 v2 health survey 
compared with an age and sex matched population from the same region. Therefore, 
NCC appears to impact patients’ overall health and their ability to perform daily tasks. 
 Many of the NCC patients in this study did not know about T. solium in pigs or 
humans. They were unaware of the parasite’s life cycle. People in endemic areas of 
Mexico need better education about the disease and its mode of transmission. 
In conclusion, this is first attempt to obtain an estimate of the non-monetary 
burden of NCC in Mexico using the DALY. These estimates suggest that healthy years 
of life continue to be lost annually in Mexico, with a continued effort needed to control 
this parasitic disease in endemic regions.  
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APPENDIX A 
 
 
 
Neurocysticercosis Health Study (intake form) 
 
Individual ID   
 
Abstractor ID   
 
Hospital/Clinic ID 
 
Today’s Date   
                        ( d    d    m   m   y    y ) 
 
Date of Birth  
                        ( d   d    m  m    y    y  ) 
 
Gender:          (male)            (female) 
 
State of Residence:       (Mexico City)               (Mexico State)                (Michoacan)              
   (Guerrero)  
                                      (Morelos)                     (Other_______________) 
 
Village of Residence __________________________   
 
Postal Code  
 
Highest Education Level Completed:    None       Elementary school 
      High school      Some college 
      Technical degree       Graduate degree   
      University degree    
 
Insurance Type:      (IMSS)       (SSA)       (no insurance)      ( ISTEE)      (Not 
reported/unknown) 
 
Payment Classification: (for SSA)                  (levels 0 - 6) 
 
NCC/seizure-associated reason(s) for today’s visit. Follow-up for: (check all that apply) 
1. Epilepsy (>1 afebrile seizure not associated with an acute CNS process)    
2. Acute symptomatic seizures                                                                       
3. Single seizure                                                                                     
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4. Dementia                                                                                                        
5. Hydrocephalus                                                  
6. Vasculitis/stroke          
7. Increased intracranial pressure       
8. Severe headaches lasting more than 3 days      
9. Other ___________________________     
          
Medical History: 
 
HIV Status:          Positive      Negative     Not reported / unknown 
 
AIDS Status:       Positive      Negative     Not reported / unknown
  
 Has the patient ever been diagnosed with any of the following? (check all that apply)                                                                
                                                                                              
              If yes, date of 1
st
 diagnosis      
Information Source 
 
        (d     d      m   m    y      y)  
     
                                                                                                                             
1. Epilepsy                                                                        History     
 File      Other record 
  
2. Acute symptomatic seizures                                             History     
 File      Other record 
 
3. Single seizure                                                              History     
 File      Other record 
 
4. Dementia                                                        History     
 File      Other record 
                                                                                                                                                                               
5. Hydrocephalus                                                                  History     
 File      Other record                                        
 
6. Vasculitis/stroke                                                                     History     
 File      Other record                                         
 
7. Increased intracranial pressure                                     History     
 File      Other record                            
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8. Severe headaches (>3 days)                                                   History     
 File      Other record     
                                      
Seizure types: (check all that apply) 
1. Atonic            
2. Absence           
3. Tonic/clonic         
4. Myoclonic         
5. Simple partial         
6. Complex partial         
7. Partial seizures with secondary generalization    
8. Other type_________________________     
9. Type not specified         
10. Never had seizures          
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APPENDIX B  
 
 
 
GENERAL QUESTIONNAIRE FOR PATIENTS AT THE INNN AND IMSS 
 
Patient study code__________________________________________ 
Last name : _______________________ First name : _________________________ 
      Questionnaire number  _______________ 
      District ____________________________ 
      Village _____________________________ 
      Hut (house) number __________________ 
      How long have you lived in this village? 
(yrs.) 
 
1 How old are you? _____________ (years) 
2 What is your date of birth?____ Day         _____  Month        _______  Year 
3 Sex   1 Male     2 Female   
4 What is the highest schooling grade you have completed?   
1 None    2 Primary school  
3 High School   4 College   
5 What further education have you completed?   
 1 None    2 Technical school  
3 University   4       Aprentice diploma 
6 What is your occupation?  
1 Self-employed (crafts)  2 Self-employed (farmer)  
3 Housewife    4 House maid 
5 Employed by someone else (specify occupation) _________________________ 
 6.1 What is your income (per month): _____________________________________ 
7 How many days of work have you missed in the past month because of illness? 
____days 
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 7.1 If you are not employed outside the home (i.e. house wife), how many days in 
the past month have you been unable to attend to your daily chores because of 
illness? _______ days 
8 How many days of work have you missed in the past year because of illness? ______ 
days 
 8.1 If you are not employed outside the home, how many days in the past year have 
you been unable to attend to your daily chores because of illness? _____ days 
9 Where do you usually get your drinking water?     
1 River    2 Bore-hole 
3 Well    4 Other [Specify] _________________ 
10 How often do you boil your drinking water?      
1 Always   2 Almost always  
3 Sometimes  4 Never  
11 How often do you eat pork?        
1 At least once a month  2 Less than once a month but at least once a year 
3 Less than once a year  4 Never [Skip to Q13]  
12.1 How is the pork that you eat prepared? [Check all that apply.]  
1 Boiling          2 BBQ 
3 Fried          
4Others[Specify]______________________________ 
12.2 Have you ever eaten [Read list and check all that apply.] 
1 Raw pork meat   2 Rare pork meat 
3 Medium cooked pork meat 4 Well done pork meat 
      5 Cannot remember, do not know 
13 Do you have a toilet at home? 
1 Yes    2 No [Skip to Q14] 
 13.1 How often do you use a toilet when you have to defecate? 
     1 Always  2 Sometimes   3 Never 
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14 Do you keep pigs? 
 Yes [please fill in the pig questionnaire]   No  
15. Have you ever owned pigs? [If they answer “yes”, ask when they owned pigs]  
 Yes [please fill in the pig questionnaire]   No  
15.1 What kind of pigs were they? 
1 Europeos    2 Criollos 
3 Europeos y Criollos   4 Don’t know 
16. Were you ever told that your pigs or piglets were infected with cysts (cysticercosis)?  
 Yes [please fill in the pig questionnaire]   No  
 16.1 When were you told that your pig or piglets were infected with cysts 
(cysticercosis)?  
1 In the past year   2 One to five years ago 
3 More than 5 years ago    4 Never told 
5 Don’t know 
 16.1.1 When that happened, were you able to sell your pigs?  
1 Sold all    2 Sold more 
3 Could not sell     4 Don’t know  
16.1.2 When this happened, at what price did you sell your pigs (aged more than 4 
months)? ___________________________________ 
16.1.3 When this happened, at what price did you sell your pigs (aged 4 months or 
less)? ___________________________________ 
17  Have you ever seen or heard of white nodules (rice) in pig carcasses?   
      1 Yes       2 No 
 17.1 Where can you find nodules on a live pig? 
1 It is not possible to find them on a live pig  
2 Under the skin 
3 Under the tongue 
 4 Don’t know 
5 Somewhere else, please specify___________________________________ 
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 17.2 How do pigs get these nodules? 
1 By eating human feces   2 By eating pig feces 
3 From another infected pig 5 Don’t know 
4 Other, please specify___________________________________ 
 17.3 What would you do if you discovered that your pig had nodules? 
1Sell the pig    2 Treat it with herbs 
3 Pierce the nodules  5 Don’t know 
4 Other, please specify___________________________________ 
18  Have you ever heard of tapeworm infection in humans?  
      1 Yes       2 No [Skip to Q 19]    
 18.1 How did you learn about it? 
1 From a doctor   2 From a friend or family member 
3 From a traditional healer  4 From the radio / newspaper 
5 Other [Specify] ________________________________________________ 
 18.2  How does a person know if they have a tapeworm?  
1 They can see it in their faeces 2 They have diarrhoea 
3 They have fever   4 Other [Specify] ___________________ 
5 I don’t know 
 18.3  Have you ever had a tapeworm or seen small parts (segments) of worms that 
look like rice grains in your faeces? (Show photographs of proglottids) 
1 Yes               2 No [Skip to Q 18.4] 
3 I don’t know/cannot remember [Skip to Q 18.4] 
18.3.1 When that happened, what did you do? [Read list and check all that apply] 
 1 Went to a primary health care provider (hospital, clinic, dispensary)
  2 Went to the pharmacy to get a drug to treat it 
 3 Went to a traditional healer   
4 Did nothing 
 5 I cannot remember, I do not know 
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18.4 How does a person get tapeworm infection?  
1 They do not wash their hands          2 They eat undercooked pig meat 
3 They are in contact with an infected person      4 Other [Specify] ______ 
5 I don’t know 
19 Have you ever had skin nodules or hard lumps under the skin?  [Show photograph of 
person with subcutaneous cysticercosis nodules]             
1 Yes, currently has   2 Yes in the past year, but not currently 
3 Yes, one year or more ago, but not currently 4 No 
5 Cannot remember, do not know 
20 Have you ever had bad headaches that lasted more than a few days?   
 1 Yes, currently has   2 Yes in the past year, but not currently 
3 Yes, one year or more ago, but not currently 4 No 
5 Cannot remember, do not know 
21 Have you ever had any of the following? 
21.1 Sudden loss of consciousness and episodes of incontinence or foaming of the mouth 
or tongue biting? 
 1 Yes, currently has   2 Yes in the past year, but not currently 
3 Yes, one year or more ago, but not currently 4 No 
5 Cannot remember, do not know 
21.1.1 If yes, how often has this happened? 
1Only once    2 More than once 
21.1.2 How old were you when this happened for the first time? 
 1 When I was a child (less than 15 years old) 
 2 When I was juvenile (15-19 years old) 
3 When I was an adult (more than 20 years old) 
4 Don’t know 
21.1.3 When did this occur for the first time? 
 1 In the last twelve months 2 One to two years ago 
3 Three to four years ago 4 More than 5 years ago 
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5 Don’t know 
21.2 A brief period of absence(s) or loss(es) of contact with the surroundings that starts 
suddenly? 
 1 Yes, currently has   2 Yes in the past year, but not currently 
3 Yes, one year or more ago, but not currently 4 No 
5 Cannot remember, do not know 
21.2.1 If yes, how often has this happened? 
1Only once    2 More than once 
21.2.2 How old were you when this happened for the first time? 
 1 When I was a child (less than 15 years old) 
 2 When I was juvenile (15-19 years old) 
3 When I was an adult (more than 20 years old) 
4 Don’t know 
21.2.3 When did this occur for the first time? 
 1 In the last twelve months 2 One to two years ago 
3 Three to four years ago 4 More than 5 years ago 
5 Don’t know 
21.3 Uncontrollable twitching or jerking or abnormal movements of one or more limb(s) 
(convulsions) that starts suddenly and lasts for a period of a few minutes? 
 1 Yes, currently has   2 Yes in the past year, but not currently 
3 Yes, one year or more ago, but not currently 4 No 
5 Cannot remember, do not know 
21.3.1 If yes, how often has this happened? 
1Only once    2 More than once 
21.3.2 How old were you when this happened for the first time? 
 1 When I was a child (less than 15 years old) 
 2 When I was juvenile (15-19 years old) 
3 When I was an adult (more than 20 years old) 
4 Don’t know 
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21.3.3 When did this occur for the first time? 
 1 In the last twelve months 2 One to two years ago 
3 Three to four years ago  4 More than 5 years ago 
5 Don’t know 
21.4 Sudden onset of a brief period of hearing or smelling or seeing things that are not 
there or feeling strange body sensations? 
 1 Yes, currently has   2 Yes in the past year, but not currently 
3 Yes, one year or more ago, but not currently 4 No 
5 Cannot remember, do not know 
21.4.1 If yes, how often has this happened? 
1Only once    2 More than once 
21.4.2 How old were you when this happened for the first time? 
 1 When I was a child (less than 15 years old) 
 2 When I was juvenile (15-19 years old) 
3 When I was an adult (more than 20 years old) 
4 Don’t know 
21.4.3 When did this occur for the first time? 
 1 In the last twelve months 2 One to two years ago 
3 Three to four years ago 4 More than 5 years ago 
5 Don’t know 
21.5 Were you ever told that you had epilepsy or that you had an epileptic seizure? 
 1 Yes, currently has   2 Yes in the past year, but not currently 
3 Yes, one year or more ago, but not currently 4 No 
5 Cannot remember, do not know 
21.5.2 How old were you when this happened for the first time? 
 1 When I was a child (less than 15 years old) 
 2 When I was juvenile (15-19 years old) 
3 When I was an adult (more than 20 years old) 
4 Don’t know 
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21.5.3 When did this occur for the first time? 
 1 In the last twelve months 2 One to two years ago 
3 Three to four years ago 4 More than 5 years ago 
 5 Don’t know 
21.6 Have you ever had seizures or fits? 
 1 Yes, currently has   2 Yes in the past year, but not currently 
3 Yes, one year or more ago, but not currently 4 No 
5 Cannot remember, do not know 
21.6.1 If yes, how often has this happened? 
1Only once    2 More than once 
21.6.2 How old were you when this happened for the first time? 
 1 When I was a child (less than 15 years old) 
 2 When I was juvenile (15-19 years old) 
3 When I was an adult (more than 20 years old) 
4 Don’t know 
21.6.3 When did this occur for the first time? 
 1 In the last twelve months 2 One to two years ago 
3 Three to four years ago 4 More than 5 years ago 
5 Don’t know 
 
If the interviewee has answered “no” to questions 21.1-21.6, the interview is finsished. 
Otherwise, please continue with the questionnaire. 
22 Have you had the following? 
22.1 Head injury that made you lose consciousness? 
1 Yes    2 No 
22.2 Meningitis (brain infection) during childhood? 
1 Yes    2 No 
22.2.1 If yes, when did your seizure symptoms start? 
 1 Before meningitis  2 Soon after meningitis 
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3 Long time after meningits 4 Don’t know 
23 What happens to you when you have a seizure or fit?_____________________ 
24 Have you ever hurt yourself when you lose consciousness or during a seizure? 
1 Yes    2 No 
3 I do not lose consciousness or have seizures [Skip to Q 25] 
4 Cannot remember [Skip to Q 25]  
 24.1 If yes, how did you hurt yourself? 
1 Fell in the fire  2 Fell in the water 
3 Fell off your bicycle 4 Fell while walking along the road 
5 Cut yourself  6 Other [Specify] _______________________ 
25 Is there someone in your household with epilepsy or seizures?     
1 Yes, currently is  2 Yes in the past year, but not currently 
3 Yes, one year or more ago, but not currently   4 No   
25.1 (If yes) Who in your household has epilepsy or seizures? [check all that apply] 
 1 Mother     2 Father 
3 Brother/sister  4 Child (how many) __________ 
5 Other relative (how many) __________ 6 Other [specify] _____________ 
 
(Interviewer: Read the following statement) 
Now I want to ask you a few questions about your treatments for [insert name of 
symptom or condition they reported having in question 21.1-21.6] 
 
26 Before you came to this hospital, had you ever consulted a health provider because of 
this condition? 
2 No [Skip to Q 26.6]   3 Cannot remember [Skip to Q 26.6] 
1 Yes 
26.2 Before you first came to this hospital for treatment, when was the last time you 
had consulted a health provider for your condition? 
1 Within the previous month  2 Within the previous year 
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3 From one (1) to five (5) years before 4 More than five (5) years before 
5 Cannot remember, not sure 
26.3 Before you first came to this hospital for treatment, what kind of health 
provider(s) had you consulted and how many times in the past 5 years [check any 
that apply]? 
1 A physician /_______ times (26311)    
2 A neurologist/___________times (26322) 
3 A nurse/_________ times (26331)     
4 A herbalist/_________ times (26341) 
5 A traditional healer /_____times (26351)    
6 A psychiatrist/psychologist/ __ times (26361) 
7 Other (specify _____________________________)/________ times (26371) 
8 Cannot remember, not sure 
26.4 Before you first came to this hospital, how much did it cost each time you 
consulted with one health provider [specify the currency used]? 
1 A physician/ (26411)___________   
2 A neurologist/(26421)_________________ 
3 A nurse/ (26431) _______________ 
4 A herbalist ____________ 
5 A traditional healer/(26451) 
6 A psychiatrist / psychologist/(26461) _____________________   
7 Other (specify ___________________________)(26471) _______________ 
8 Cannot remember, not sure 
9 I never pay because the government covers my health expenses 
26.5 Before you came to this hospital, how far did you have to travel to go to the 
health provider from your house and how did you get there (1 foot, 2 bicycle, 3 
bus, 4 train, 5 taxi, 6 car, 7 other)? 
1 Physician at/ _____ km reached by___  
2 Neurologist at ____ km reached by___ 
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3 Nurse at ____ km reached by____  
4 Herborist at ____ km reached by____ 
5 Traditional healer at _____ km reached by______ 
6 A psychiatrist / psychologist at _____ km reached by______ 
7 Other (specify ___________________) at _____ km reached by_________ 
  8 Cannot remember  
27. Have you ever been hospitalized because of this condition? 
2 No   3 Cannot remember 
1 Yes 
27.2 How many times have you been hospitalized in the past 5 years?____________ 
27.3 When were you last hospitalized (in months)?_________________________ 
27.3.1 How many days did you stay in the hospital?_________________________ 
27.3.2 How much did it cost?________________________________________ 
27.3.3 How far is the hospital from your house (in km)?_____________________ 
27.3.4 How do you usually come to this hospital? [Check all that applies] 
 and how do you get here (1 foot, 2 bicycle, 3 bus, 4 train, 5 taxi, 6 car, 7 other)? 
1 By foot    2 by bicycle 
3 By bus    4 By train 
5 By taxi     6 by car 
7 Other (specify ________________________)  
28. Did you ever have any medical tests because of this condition? 
2 No   3 Cannot remember 
1 Yes 
28.2 What kind of test was it (check all that are appropriate)? 
 1 Blood test for cysticercosis  2 CT scan of the brain 
3 X-ray of the brain   4 MRI of the brain 
4 EEG     5 Cannot remember, do not know 
28.3 When was the last time you had a medical test for this condition? 
 1Within the past month  2 Within the past year 
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3 From one to five years ago 4 More than 5 years ago 
 5 Don’t know 
28.4 Before you first came to this hospital, how much did it cost each time you 
consulted with one health provider [specify the currency used]? 
1 Blood test for cysticercosis________ 2 CT brain scan______________ 
3 Skull X-ray_______________  4 MRI of the brain____________ 
5 EEG________________   6 Other _________________ 
28.5 How far from your house did you have to travel for this test and how did you 
get there? 
 Blood test for cysticercosis / _____ km reached by___  
2 CT brain scan ____ km reached by___ 
3 Skull X-ray ____ km reached by____  
4 MRI of the brain ____ km reached by____ 
5 EEG _____ km reached by______ 
6 Other _____ km reached by______ 
29. Before you came to this hospital, were you ever treated with drugs for this condition? 
2 No (the interview is finished)  
3 Can’t remember, do not know (interview is finished) 
1 Yes 
29.2 When was the last time you used medication for your condition? 
1 Within the previous month  2 Within the previous year 
3 From one (1) to five (5) years before 4 More than five (5) years before 
5 Cannot remember, not sure 
29.3 What medication was it and how many times per year did you have to use 
some?  
1 Carbamazepine/Tegretol______   2 Phenytoin/Dihydan_________  
3 Valproic acid/Dépakin________   4 Phenobarbital/Gardénal ______ 
5 Traditional medicine ________    6 Other (specify _____) _______  
7 Can not remember, not sure 
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29.4 How much did it cost each time you bought this medication? 
1 Carbamazepine/Tegretol______   2 Phenytoin/Dihydan_________  
3 Valproic acid/Dépakin________   4 Phenobarbital/Gardénal ______ 
5 Traditional medicine ________      6 Other (specify _____) _______  
7 Can not remember, not sure 
 
THIS IS THE END OF THE INTERVIEW 
THANK YOU VERY MUCH FOR YOUR COOPERATION 
 
INTERVIEWER: ______________________ 
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APPENDIX C  
 
 
 
PIG QUESTIONNAIRE 
District _________________________________ 
Village __________________________________ 
Hut (house) number _______________________ 
Last Name : ________________________ First Name _________________________ 
       
What is your position in the household? 
1 Household head (mother)   2 Household head (father)  
3 One of the daughters    4 One of the sons 
6 Other [Specify]________________________ 
[Interviewer: If the person currently keeps pig, go to Q2, if the person owned pigs in the 
past, go to Q12] 
 
2.  How many of each type of pig do you keep? [mark all that apply] 
 1 Foreign ____________    2 Native _____________ 
 3 Doesn’t know type, but total number is _____  
 4 Does not know number or type______________ 
3. How many of these pigs are owed by your household? __________________ 
[indicate a number] 
4. How many pigs do you keep for each of these reasons? [Read each option and 
indicate the number kept for that reason] 
  Home eating ______________   Sell live animals (not to abattoir)  
  Sell the meat to someone else ________  Sell the pig to the abattoir _____ 
  Raise pigs ______________    Other [Specify]______________ 
5. How do you keep your pigs? [read questions 5.1 to 5.4 one by one] 
 5.1 During seeding season 
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   In a pen      Free range 
   Tethering (tied up?)               Other [Specify]______________ 
 5.2 During growing season 
   In a pen      Free range 
   Tethering      Other [Specify]______________ 
 5.3 During cropping season 
   In a pen      Free ranged 
   Tethering      Other [Specify]______________ 
 5.5 During fallowing season 
   In a pen      Free ranged 
   Tethering      Other [Specify]______________ 
6. What do your pigs eat? [check all that apply] 
 Pasture      Kitchen leftovers 
 Commercial feeds     Other [Specify]______________ 
7. How often do you slaughter pigs at home?           
 Never [Skip to Q 8]   
 Cannot remember, do not know [Skip to Q8] 
 At least once a month   
 Less than once a month but at least once a year 
 Less than once a year   
 7.1 If ever, how often was the meat inspected by a meat inspector?  
 Always     Almost always  
 Sometimes    Never   
 Cannot remember, do not know 
8. What price do you usually sell your pigs when they are ready to be slaughtered 
[specify the currency used, this can be money or barter]? _________________________ 
8.1 What price do you usually sell your live pigs to someone else to raise [specify 
the currency used, this can be money or barter – specify prices at different pig 
weights if necessary]? _____________________________________________ 
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8.2 What price do you usually sell mature sows to someone else for raising? 
[specify the currency used, this can be money or barter] 
_________________________________________________________________ 
9. What price do you usually sell your piglets (aged 4 months or less) [specify the 
currency used, this can be money or barter]? _______________________ [Skip to Q11] 
10. For what do you use the profits from selling your pigs ? [check all that apply] 
 To send children to school   To buy food  
 To invest in a business    For savings  
 Other [Specify] _________________________________________________ 
11. Have you ever seen or heard of white nodules (rice) in pig carcasses? 
 Yes      No [Interview is over] 
 11.1  Where can you find nodules on a live pig?  
 It is not possible to find them on a live pig   
 Under the skin   Under the tongue 
 I don’t know   Somewhere else [Specify]______________ 
 11.2  How do pigs get these nodules? 
 By eating human faeces   By eating pig faeces 
 From another infected pig    Other [Specify] ___________________ 
 I don’t know 
 11.3 What would you do if you discovered that your pig had these nodules? 
 Sell the pig     Treat it with herbs 
 Pierce the nodules    Other [Specify] ____________________ 
 I don’t know 
11.4 What price could you sell a pig with nodules when they are ready to be 
slaughtered [specify the currency used, this can be money or barter]? 
__________________________________________________________________ 
 
11.4.1 What price would you sell a live pig with nodules to someone else for 
raising? 
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_________________________________________________________________ 
11.4.2 What price would you sell a mature sow with nodules to someone else for 
raising? 
_________________________________________________________________ 
11.5 What price could you sell piglets with nodules (aged 4 months or less) 
[specify the currency used, this can be money or barter]? 
________________________________________________________ 
  
 
THIS IS THE END OF THE INTERVIEW 
THANK YOU VERY MUCH FOR YOUR HELP 
 
INTERVIEWER: ___________________________DATE OF 
INTERVIEW:_____________ 
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APPENDIX D 
 
 
 
Estudio de neurocisticercosis (NCC) 
Formato para registro de la primera vez que se diagnosticó NCC 
 
No. Expediente 
 
Identificación del encuestador 
 
Hospital/Clínica:   (INNN)             (CMNSXXI)              (INPed)               (SSA Uruapan)  
                              (Otro)  
(Nombre:_______________________________________________________) 
 
Fecha de hoy  
                        ( d    d    m   m   a    a ) 
 
Fecha de nacimiento  
                                    ( d   d    m   m    a    a  ) 
 
Género:          (hombre)            (mujer) 
 
Estado de residencia:       (México DF)               (Estado de México)                (Michoacán)              
   (Guerrero)  
                                         (Morelos)                   (Otro) (especifique_______________________) 
 
Comunidad o ciudad de residencia __________________________________________ 
 
Código Postal 
 
Nivel de estudios concluido      Ninguno       Primaria 
      Secundaria      Preparatoria 
      Escuela técnica      Licenciatura 
      Posgrado 
 
Tipo de seguro médico:      (Popular)       (IMSS)       (ISSSTE)      (no asegurado)      
(no sabe) 
                                            (Privado)  (Nombre:______________________)      (Otro) 
(Nombre:__________________) 
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Nivel de cuota de recuperación en la SSA: (0 a 6) 
 
Visita de hoy debida a NCC/convulsiones. Causa de seguimiento: (marcar las 
necesarias) 
10. Epilepsia (>1 convulsión no febril y no asociada a un proceso agudo del SNC)  
11. Convulsiones agudas sintomáticas       
12. Convulsión única          
13. Demencia          
14. Hidrocefalia          
15. Vasculitis                                                                                                         
16. EVC          
17. Hipertensión intracraneana        
18. Cefalea grave con duración mayor a 3 días      
19. Otra causa, especifique_________________________________________  
 
Historia Médica: 
VIH:          Positivo      Negativo     No reportado / 
desconocido 
 
SIDA:        Positivo      Negativo     No reportado / 
desconocido 
 
El paciente ha sido diagnosticado alguna vez con: (marcar las necesarias) 
 
            En caso afirmativo, fecha del Dx           Fuente 
de información 
       (d     d      m   m    a      a)  
     
9. Epilepsia         Historia   
 Archivo    Otra        
 especifique_________________ 
 
10. Convulsiones agudas sintomáticas      Historia   
 Archivo    Otra        
 especifique_________________ 
 
11. Convulsión única          Historia   
 Archivo    Otra        
 especifique_________________ 
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12. Demencia         Historia   
 Archivo    Otra        
 especifique_________________ 
 
13. Hidrocefalia         Historia   
 Archivo    Otra        
 especifique_________________ 
 
14. Vasculitis                                                                                          Historia   
 Archivo    Otra        
 especifique_________________ 
 
15. EVC         Historia   
 Archivo    Otra        
 especifique_________________ 
 
16. Hipertensión intracraneana       Historia   
 Archivo    Otra        
 especifique_________________ 
 
17. Cefalea grave (>3 días)       Historia   
 Archivo    Otra        
 especifique_________________ 
 
Tipo de convulsiones: (marcar las necesarias) 
11. Atónica       
12. Ausencias       
13. Tónico/clónica       
14. Mioclónica       
15. Parcial simple       
16. Parcial compleja       
17. Convulsión parcial con generalización secundaria  
18. Otro tipo, especifique______________________  
19. Tipo no especificado       
20. Nunca ha tenido convulsiones    
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APPENDIX E  
 
 
 
ESTUDIO DE NEUROCISTICERCOSIS HUMANA (NCC)  
CUESTIONARIO GENERAL 
    Número de expediente  _______________________ 
    Municipio _________________________________ 
    Comunidad ________________________________ 
    Número de casa (lote, manzana, etc.) _____________ 
    ¿Cuántos años ha vivido en esta comunidad?________ 
¿Tiene seguro médico?    Si    No   No sabe 
Tipo de seguro médico     Popular       IMSS       ISSSTE  
   Privado 
 
1 ¿Qué edad tiene? _____________ (años) 
2 ¿Cuál es su fecha de nacimiento?____ Día        _____  Mes        _______  Año 
3 Género  1 Hombre     2 Mujer   
4 ¿Cuál es el último grado de escolaridad que terminó?   
1 Ninguno    2 Primaria 
3 Secundaria     4  Preparatoria 
5 ¿Qué otro tipo de educación ha terminado? 
1 Escuela técnica   2 Licenciatura 
3 Posgrado     
6 ¿Cuál es su ocupación? _________________________________________ 
 6.1 Si trabaja, cual es su salario mensual? 
7 ¿Puede calcular cuántos días ha faltado a su trabajo por enfermedad en el último mes? 
_________       2 No puede calcular 
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 7.1 Si no tiene un empleo oficial, ¿Puede calcular cuántos días no ha podido realizar 
sus tareas diarias en el último mes? _____   2 No puede calcular 
8 ¿Puede calcular cuántos días ha faltado a su trabajo por enfermedad en el último año? 
______         2 No puede calcular 
 8.1 Si no tiene un empleo oficial, ¿Puede calcular cuántos días no ha podido realizar 
sus tareas diarias en el último año? _____   2 No puede calcular 
9 ¿Por lo general de dónde obtiene su agua para beber?     
 1 Río  2 Pipa  3 Pozo  4 Embotellada 
5 Otro [Especifique] _________________ 
10 ¿Hierve su agua para beber?       
1 Siempre   2 Casi siempre  
3 A veces   4 Nunca  
11 ¿Con qué frecuencia come cerdo?        
1 Por lo menos una vez al mes 2 Menos de 1 vez al mes pero por lo menos 1 vez 
al año 
3 Menos de una vez al año 4 Nunca [Pase a la P13]  
12.1  ¿Cómo se prepara el cerdo que usted come? [Marque todas las que se apliquen.] 
1 Carnitas    2 Chorizo 
3 Embutidos   4 Otro 
[Especifique]______________________________ 
12.2  ¿Alguna vez ha comido [Marque todas las que se apliquen.] 
1 Carne de cerdo cruda   2 Carne de cerdo poco cocida 
3 Carne de cerdo medio cocida 4 Carne de cerdo bien cocida 
      5 No recuerdo, no sé 
13 ¿Tiene un baño o letrina en su casa? 
1 Sí    2 No [Pase a la P14] 
 13.1 ¿Con qué frecuencia usa un excusado cuando tiene que defecar? 
     1 Siempre   2 A veces   3 Nunca 
 13.2 ¿Con qué frecuencia defeca en el campo o en las milpas? 
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     1 Siempre   2 A veces   3 Nunca 
14 ¿Cría cerdos? 
 Sí (por favor conteste el cuestionario de cerdos)   No  
15 ¿Alguna vez ha tenido cerdos? [Si la respuesta es “sí”, pregunte cuándo] 
1 Sí, el año pasado   2 Sí, hace de 1 a 5 años  
3 Sí, hace más de 5 (cinco años 4 No [Pase a la P 17]   
 15.1 ¿Qué tipo de cerdos eran? 
1 Europeos (blancos)   2 Criollos (oscuros) 
3 Europeos y criollos   4 No recuerda, no sabe 
16  ¿Alguna vez le dijeron que sus cerdos tenían grano, granillo o tomate (cisticercosis)? 
      1 Sí    2 No [Pase a la P 17] 
16.1. ¿Cuándo le dijeron que sus cerdos tenían grano, granillo o tomate 
(cisticercosis)? 
1 El año pasado      2 Hace de 1 a 5 años   3 Hace más de 5 
años 
4 Nunca me dijeron (Pase a la P 17) 5 No recuerdo, no sé (Pase a la P 
17) 
16.1.1 ¿Pudo vender sus cerdos después de que le dijeron que tenían grano, 
granillo o tomate? 
1 Vendí todos 2 Vendí algunos  3 No pude venderlos [Pase a la P 
17] 
5 No recuerdo, no sé [Pase a la P 17] 
16.1.2  Cuando sucedió eso, ¿a qué precio vendió sus cerdos adultos 
(Especifique la forma de pago, puede ser dinero o trueque)? ________________ 
16.1.3  Cuando sucedió eso, ¿a qué precio vendió sus cerditos de 4 meses de 
edad o menos (Especifique la forma de pago, puede ser dinero o trueque)? _____ 
17  ¿Alguna vez ha visto o escuchado grano, granillo o tomate en la canal de cerdo? 
 1 Sí    2 No [Pase a la P 18] 
 17.1  ¿Dónde se pueden encontrar grano, granillo o tomate en un cerdo vivo?  
1 No es posible encontrarlos en un cerdo vivo   
2 Debajo de la piel              3 Debajo de la lengua 
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4 No sé               5 En algún otro lugar [Especifique] ____ 
 17.2  ¿Por qué sale grano, granillo o tomate a los cerdos? 
1 Por comer excremento humano 2 Por comer excremento de cerdo 
3 De otro cerdo infectado    4 Otro [Especifique] _______________ 
5 No sé 
 17.3 ¿Qué haría si descubriera que su cerdo tiene grano, granillo o tomate? 
1 Lo vendería   2 Lo trataría con hierbas 
3 Picar los granos   4 Otro [Especifique] ________________ 
5 No sé 
18  ¿Alguna vez ha escuchado de una infección por solitaria o tenia en humanos?  
      1 Sí       2 No [Pase a la P 19]   
 18.1 ¿Cómo supo de ella? 
1 Por un doctor   2 Por un amigo o familiar 
3 Por un curandero   4 En la radio / periódico 
5 Otro [Especifique] _____________________________________________ 
 18.2  ¿Cómo sabe una persona si tienen una solitaria?  
1 Lo puede ver en su excremento 2 Tiene diarrea 
3 Tiene fiebre   4 Otro [Especifique] ________________ 
5 No sé 
 18.3  ¿Alguna vez ha tenido una solitaria o visto pequeñas partes (segmentos) de 
gusanos que parecen como tallarines planos en su excremento? (Muestre fotografías 
de proglótidos) 
1 Sí               2 No [Pase a la P 18.4] 
3 No sé / no recuerdo [Pase a la P 18.4] 
18.3.1 Cuando sucedió eso, ¿qué hizo? [Marque todas las que se apliquen] 
 1 Fui al centro de salud, hospital, clínica o dispensario  
  2 Fui a la farmacia para comprar la medicina y tratarlo 
 3 Fui con un curandero  4 No hice nada 
 5 No recuerdo, no sé 
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 18.4  ¿Cómo se infecta una persona con solitaria?  
1 No se lava las manos  
       2 Come carne de cerdo que no está bien cocida 
3 Está en contacto con una persona que tiene solitaria      
4 Otro [Especifique] ________ 
5 No sé 
 18.5  ¿Sabe si algún familiar o persona que vive en su casa tiene o ha tenido una 
solitaria? 
1 Sí               2 No [Pase a la P 19] 
18.5.1 ¿Hace cuanto tiempo la tuvo? 
1 En los últimos 6 meses  2 Hace 1 a 2 años 
 3 Hace 3 a 5 años  4 Hace más de 5 años 
 5 No recuerdo, no sé 
19 ¿Alguna vez ha tenido nódulos en la piel o bolitas duras debajo de la piel?  [Muestre 
la fotografía de la persona con nódulos subcutáneos por cisticercosis]         
1 Sí, actualmente los tengo  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora 4 No 
5 No recuerdo, no sé 
20  ¿Alguna vez ha tenido dolores de cabeza graves que duran varios días?    
1 Sí, actualmente los tengo  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora 4 No 
5 No recuerdo, no sé 
21 ¿Alguna vez ha tenido alguno de los siguientes casos? 
21.1 Pérdida repentina de la conciencia y episodios de incontinencia o espuma en la 
boca o morderse la lengua 
1 Sí, actualmente los tengo             2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora  
4 No [Pase a la P 21.2]             5 No recuerdo, no sé   
  21.1.1 (Si la respuesta es sí) ¿Cuántas veces le ha sucedido esto? 
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1 Solamente una vez  2 Más de una vez 
  21.1.2 ¿Qué edad tenia cuando esto le sucedió por primera vez? [Indicar el edad 
si lo se]  
   1 Cuando era niño (menos de 15 anos) y tenia ________________años 
   2 Cuando era joven (15-19 anos) y tenia _____________________años 
   3 Desde que soy adulto (20 anos o mas) y tenia _______________años 
   4 No recuerdo, no se 
  21.1.3 Cuando le sucedió esto por primera vez? 
   1 Durante el año (12 meses) pasado  
   2 De 1 a 2 años 
   3 De 3 a 4 años 
   4 Al menos 5 años 
   5 No recuerdo, no se 
21.2 Un período breve de ausencia o pérdida de contacto con sus alrededores que 
empieza de repente  
1 Sí, actualmente lo tengo  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora  
4 No [Pase a la P 21.3]   5 No recuerdo, no se [Pase a la P 
21.2.1] ¿Cuántas veces le ha sucedido esto? 
1 Solamente una vez   2 Más de una vez 
  21.2.2 ¿Qué edad tenia cuando esto le sucedió por primera vez? [Indicar el edad 
si lo se]  
   1 Cuando era niño (menos de 15 años) y tenia ________________ años 
   2 Cuando era joven (15-19 años) y tenia ____________________ años 
   3 Desde que soy adulto (20 años o mas) y tenia _______________años 
   4 No recuerdo, no se 
  21.2.3 ¿Cuando le sucedió esto por primera vez? 
   1 Durante el año (12 meses) pasado  
   2 De 1 a 2 años 
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   3 De 3 a 4 años 
   4 Al menos 5 años 
   5 No recuerdo, no se 
 21.3 Sacudidas o tirones (alferecias) o movimientos anormales incontrolables de una 
o más extremidades (convulsiones) que empiezan de repente y duran algunos 
minutos 
1 Sí, actualmente los tengo  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora  
4 No [Pase a la P 21.4]  5 No recuerdo, no sé [Pase a la P 21.4] 
 21.3.1 ¿Cuántas veces le ha sucedido esto? 
1 Solamente una vez  2 Más de una vez 
  21.3.2 ¿Qué edad tenia cuando esto le sucedió por primera vez? [Indicar el edad 
si lo se]  
   1 Cuando era niño (menos de 15 años) y tenia ________________ años 
   2 Cuando era joven (15-19 años) y tenia ____________________ años 
   3 Desde que soy adulto (20 años o mas) y tenia _______________años 
   4 No recuerdo, no se 
  21.3.3 ¿Cuando le sucedió esto por primera vez? 
   1 Durante el año (12 meses) pasado  
   2 De 1 a 2 años 
   3 De 3 a 4 años 
   4 Al menos 5 años 
   5 No recuerdo, no se 
21.4 Inicio repentino de un período corto de oír u oler o ver cosas que no existen o 
tener sensaciones raras en el cuerpo  
1 Sí, actualmente lo tengo  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora  
4 No [Pase a la P 21.5]  5 No recuerdo, no sé [Pase a la P 21.5] 
21.4.1 ¿Cuántas veces le ha sucedido esto? 
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1 Solamente una vez  2 Más de una vez 
  21.4.2 ¿Qué edad tenia cuando le sucedió esto por primera vez? [Indicar el edad 
si lo se]  
   1 Cuando era niño (menos de 15 años) y tenia ________________ años 
   2 Cuando era joven (15-19 años) y tenia ____________________ años 
   3 Desde que soy adulto (20 años o mas) y tenia _______________años 
   4 No recuerdo, no se 
  21.4.3 ¿Cuando le sucedió esto por primera vez? 
   1 Durante el año (12 meses) pasado  
   2 De 1 a 2 años 
   3 De 3 a 4 años 
   4 Al menos 5 años 
   5 No recuerdo, no se 
21.5 ¿Alguna vez le dijeron que tenía epilepsia o que había tenido una convulsión 
epiléptica? 
1 Sí, durante el mes pasado  2 Sí, durante el año pasado pero no el 
mes pasado 
3 Sí, hace como un año o más 4 No  
5 No recuerdo, no sé 
  21.5.2 ¿Qué edad tenia cuando le sucedió esto por primera vez? [Indicar el edad 
si lo se]  
   1 Cuando era niño (menos de 15 años) y tenia ________________ años 
   2 Cuando era joven (15-19 años) y tenia ____________________ años 
   3 Desde que soy adulto (20 años o mas) y tenia _______________años 
   4 No recuerdo, no se 
  21.5.3 ¿Cuando le sucedió esto por primera vez? 
   1 Durante el año (12 meses) pasado  
   2 De 1 a 2 años 
   3 De 3 a 4 años 
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   4 Al menos 5 años 
   5 No recuerdo, no se 
21.6  ¿Alguna vez ha tenido convulsiones o ataques?     
1 Sí, actualmente los tengo  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora  
4 No [Pase a la P 22]  5 No recuerdo, no sé [Pase a la P 22] 
21.6.1 ¿Cuántas veces le ha sucedido esto? 
1 Solamente una vez  2 Más de una vez 
  21.6.2 ¿Qué edad tenia cuando le sucedió esto por primera vez? [Indicar el edad 
si lo se]  
   1 Cuando era niño (menos de 15 años) y tenia ________________ años 
   2 Cuando era joven (15-19 años) y tenia ____________________ años 
   3 Desde que soy adulto (20 años o mas) y tenia _______________años 
   4 No recuerdo, no se 
  21.6.3 ¿Cuando le sucedió esto por primera vez? 
   1 Durante el año (12 meses) pasado  
   2 De 1 a 2 años 
   3 De 3 a 4 años 
   4 Al menos 5 años 
   5 No recuerdo, no se 
 
[Si el entrevistado ha contestado “no” a las preguntas 21.1-21.6, la entrevista ha 
terminado. Vaya a la última página y conteste las preguntas 30 y 31 tomando como 
base sus observaciones] 
MUCHAS GRACIAS POR SU COOPERACIÓN 
[De lo contrario, por favor continúe con el cuestionario] 
 
[Entrevistador: Si contestaron “sí” a cualquiera de las preguntas 21.1-21.6, pregunte lo 
siguiente. De lo contrario, pase a la P. 25.] 
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22 ¿Ha tenido alguno de los siguientes casos? 
22.1  Lesión en la cabeza por la que perdio  la conciencia?  
    1Sí     2 No [Pase a la P 22.2] 
 22.1.1  Si la respuesta fue afirmativa, ¿cuándo empezaron sus síntomas de 
convulsiones? 
1 Antes de la lesión en la cabeza   
2 Pronto después de la lesión en la cabeza 
3 Mucho tiempo después de la lesión en la cabeza  
4 No recuerdo, no sé 
 22.2  ¿Meningitis (infección cerebral) durante la infancia?   
   1 Sí     2 No  
  22.2.1  Si la respuesta fue afirmativa, ¿cuándo empezaron sus síntomas de 
convulsiones? 1 Antes de la meningitis    
   2 Pronto después de la meningitis 
 3 Mucho tiempo después de la meningitis    
 4 No recuerdo, no sé 
23 ¿Qué le pasa cuando tiene una convulsión o un ataque? ________________ 
24 ¿Alguna vez se ha lastimado cuando pierde la conciencia o durante una convulsión? 
1 Sí    2 No 
3 No pierdo la conciencia ni tengo convulsiones [Pase a la P 25] 
4 No recuerdo [Pase a la P 25]  
 24.1 Si la respuesta fue afirmativa, ¿cómo se lastimó? 
1 Caí en el fuego  2 Caí al agua 
3 Me caí de la bicicleta 4 Me caí mientras caminaba en la calle 
5 Me corté   6 Otro [Especifique] _____________________ 
25 ¿Hay alguien en su hogar que tenga epilepsia o convulsiones?     
1 Sí, actualmente  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora   4 No   
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25.1  (Si la respuesta fue sí) ¿Quién tiene epilepsia o convulsiones en su hogar? 
[Marque todas las que se apliquen]  
 1 Madre      2 Padre 
3 Hermano / hermana    4 Hijo (cuántos) ________ 
5 Otro pariente (cuántos) __________  6 Otro [Especifique] ____ 
 
(Entrevistador: Lea la siguiente declaración) 
Ahora voy a hacerle unas preguntas sobre sus tratamientos para [diga el nombre del 
síntoma o condición que dijeron tener en la pregunta 21.1-21.6] 
 
26 ¿Alguna vez ha consultado a un proveedor de atención médica (médico, neurólogo, 
enfermera,  herbolario, curandero, psiquiatra o psicólogo) por esta condición? 
2 No [Pase a la P 27]    3 No recuerdo [Pase a la P 27] 
1 Sí 
26.2 ¿Cuándo fue la última vez que consultó a un proveedor de atención médica por 
su condición? 
1 El mes pasado   2 El año pasado 
3 Hace de 1 (uno) a 5 (cinco) años 4 Hace más de 5 (cinco) años 
5 No recuerdo, no estoy seguro 
26.3 ¿Qué tipo de proveedor o proveedores de atención médica consultó y cuántas 
veces en los últimos 5 años? [marque varias casillas, según sea el caso] 
1 Un médico /_____ veces (26311)    2 Un neurólogo /______ veces (26322) 
3 Una enfermera/____ veces (26331)      4 Un herbolario /___ veces (26341) 
5  Un curandero /_____ veces (26351)    
6 Un psiquiatra / psicólogo / __ veces (26361) 
7 Otro (Especifique __________________________)/________ veces (26371) 
8 No recuerdo, no estoy seguro 
26.4 ¿Cuánto le costó cada vez que consultó a un proveedor de atención médica 
[Especifique la forma de pago]? 
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1 Un médico/ (26411)___________    2 Un neurólogo/(26421)________ 
3 Una enfermera / (26431) ____________4 Un herbolario ______________ 
5 Un curandero /(26451) 
6 Un psiquiatra / psicólogo /(26461) _____________________   
7 Otro (Especifique ________________)(26471) ______________________ 
8 No recuerdo, no estoy seguro 
8 Nunca pago porque el gobierno cubre mis gastos médicos 
26.5 ¿A qué distancia está el proveedor de salud de su casa y cómo llegó allí? (anote 
si fue: a pie 1, en bicicleta 2, en autobús 3, por tren 4, en taxi 5, en coche 6, otro 
7) 
1 Médico a / ___ km  y llegué ___  
2 Neurólogo a ____ km y llegué___ 
3 Enfermera a ____ km y llegué__  
4 Herbolario a ____ km y llegué____ 
5 Curandero a _____ km y llegué______ 
6 Psiquiatra / psicólogo _____ km y llegué______ 
7 Otro (Especifique ____________________) a _____ km y llegué_________ 
  8 No recuerdo  
27 ¿Alguna vez ha sido hospitalizado por esta condición? 
2 No [Pase a la P 28]  3 No recuerdo [Pase a la P 28] 1 Sí 
27.2  ¿Cuántas veces lo han hospitalizado en los últimos 5 años?   _________veces 
27.3 ¿Cuándo fue su última hospitalización? ________________(meses)    
27.3.1 ¿Cuántos días se quedó en el hospital? ____________________ (días) 
27.3.2 ¿Cuánto le costó (Especifique la unidad monetaria) __________________ 
27.3.3 ¿A qué distancia está el hospital de su casa? ____________________ km 
27.3.4 ¿Cómo llegó al hospital?  
1 A pie            2 En bicicleta       3 En autobús  4 En taxi 
5 En coche   6 Por tren           7 Otro [Especifique] _____________ 
28. ¿Alguna vez le han hecho exámenes médicos por esta condición? 
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2 No [Pase a la P 29]  3 No recuerdo, no sé [Pase a la P 29]
 1 Sí 
28.2 ¿Qué tipo de examen fue (marque todas las casillas que se apliquen)? 
1 Examen de sangre para cisticercosis 2 Tomografía del cerebro 
3 Rayos X del cerebro  4 Resonancia magnética del cerebro 
5 Electroencefalograma (EEG) 6 Otro [Especifique] ________________ 
7 No recuerdo, no estoy seguro 
28.3 ¿Cuándo se le hizo el último examen médico para esta condición? 
1 El mes pasado   2 El año pasado 
3 Hace de 1  a 5 años  4 Hace más de 5  años 
5 No recuerdo, no estoy seguro 
28.4 ¿Cuánto le costó cada examen [Especifique la unidad monetaria]? 
1 Examen de sangre para cisticercosis_______    
2 Tomografía del cerebro __________ 
3 Rayos X del cráneo __________    
 4 Resonancia magnética del cerebro __________ 
5 Electroencefalograma ______________  
6 Otro [Especifique] _____________ 
7 No recuerdo, no estoy seguro 
28.5 ¿Qué distancia tuvo que recorrer desde su casa para hacerse este examen y 
cómo llegó allí? (anote 1 a pie, 2 en bicicleta, 3 en autobús, 4 por tren, 5 en taxi, 
6 en coche, 7 otro)? 
1 Examen de sangre para cisticercosis a _____ km y llegué______  
2 Tomografía a _____ km y llegué______ 
3 Rayos X a _____ km y llegué________ 
4 Resonancia magnética a ______ km y llegué_______  
5 Electroencefalograma a _____ km y llegué________ 
6 Otro (Especifique ___________________) a _____ km y llegué_________ 
7 No recuerdo, no estoy seguro 
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29. ¿Alguna vez lo han tratado por esta condición? 
2 No (se termina la entrevista)  
3 No recuerdo, no sé (se termina la entrevista) 
1 Sí 
29.2 ¿Cuándo fue la última vez que usó medicamentos para su condición? 
1 El mes pasado  2 El año pasado 
3 Hace de 1 a 5 años 4 Hace más de 5 años 
5 No recuerdo, no estoy seguro  
29.3 ¿Qué medicamento usó y cuántas veces ha usado algún medicamento en el 
último año (marque varias casillas, según sea el caso)?  
1 Carbamazepina/Tegretol____ veces  
2 Fenitoína/Dihydan______ veces 
3 Ácido valpróico/Dépakin________ veces  
4 Fenobarbital/Gardénal _______veces 
5   Medicina tradicional ________ veces    
6 Otro (Especifique _________) ___veces 
7 No recuerdo, no estoy seguro 
29.4 ¿Cuánto pagó cada vez que compró este medicamento (Especifique la unidad 
monetaria usada)? 
1 Carbamazepina/Tegretol ______  2 Fenitoína/Dihydan __________ 
3 Ácido valpróico/Dépakin ________       4 Fenobarbital/Gardénal _______ 
5 Medicina tradicional ______________  
6 La recibí gratis del proveedor de atención médica (No la pagué yo) _____  
7 Otro (Especifique ___________________________________) _____  
8 No recuerdo, no estoy seguro 
 
ÉSTE ES EL FINAL DE LA ENTREVISTA 
MUCHAS GRACIAS POR SU COOPERACIÓN 
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ENTREVISTADOR: _____________________ FECHA DE LA 
ENTREVISTA____________ 
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APPENDIX F 
 
 
 
Cuestionario sobre cerdos para la gente que cría cerdos 
Municipio____________________________________ 
Comunidad __________________________________ 
Número de casa (lote, manzana, etc.)_____________________Teléfono_____________ 
Apellido ________________________ Nombre ____________________________ 
Número de expediente_____________________________________________________ 
[Entrevistador: Si la madre dijo que ella se encarga de los cerdos, lea lo siguiente]: 
Como usted está encargada de los cerdos nos gustaría hacerle algunas preguntas sobre 
sus cerdos. 
[Entrevistador: Si la persona que se encarga de los cerdos no es la madre, lea lo 
siguiente]: 
El ama de casa nos dijo que usted se encarga de los cerdos, nos permite hacerle algunas 
preguntas sobre ellos. 
¿Cuál es su posición en el hogar? 
1 Jefe del hogar (madre)   2 Jefe del hogar (padre)  
3 Una de las hijas          4 Uno de los hijos 
6 Otra [Especifique]________________________ 
2.  ¿Cuántos cerdos de cada tipo tiene? 
 1 Europeos (blancos) _______  2 Criollos (oscuros)  _________ 
 3 No sabe el tipo, pero el número total es _____ 4 No sabe el número o 
tipo 
3. ¿Cuántos de estos cerdos son propiedad del hogar? __________________ [indique un 
número] 
4. ¿Para qué cría cerdos? [Lea cada opción e indique el número que se cría por esa 
razón] 
  1. Para comer en casa ___________  
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  2. Vender animales en pie (no en rastro)______  
  3. Vender la carne   ________  4. Criar cerdos ______________ 
  5.  Otra razón [Especifique]____________  Vender el cerdo al 
rastro______________ 
5. ¿Cómo cría a sus cerdos? [Lea las preguntas 5.1 a 5.4 una por una] 
 5.1 Durante la temporada de siembra: 
   En un corral    Libres  
   Amarrados    Otro [Especifique]_____________________ 
 5.2 Durante la temporada de siembra y/o del crecimiento de sus sembradíos: 
   En un corral     Libres  
   Amarrados     Otro [Especifique]_______________ 
 5.3 Durante la temporada de cosecha: 
   En un corral     Libres  
   Amarrados     Otro [Especifique]_______________ 
 5.5 Durante la temporada de barbecho o rastrojo: 
   En un corral     Libres  
   Amarrados     Otro [Especifique]_______________ 
6. ¿Qué comen los cerdos? [Marque todas las que se apliquen] 
 Pasto     Sobras de la cocina 
 Alimentos comerciales   Tortillas 
7. ¿Con qué frecuencia sacrifica a los cerdos en casa?            
 Nunca [Pase a la 8]    No recuerdo, no sé [Pase a la 8] 
 Por lo menos una vez al mes   Menos de una vez al año 
 Menos de una vez al mes pero por lo menos una vez al año  
 7.1 El cerdo que sacrifica, lo revisa un inspector o un veterinario?  
 Siempre      Casi siempre  
 A veces     Nunca   
 No recuerdo, no sé 
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8. Por lo general, ¿a qué precio vende sus cerdos cuando están listos para ser 
sacrificados? [Especifique la unidad monetaria que usa, puede ser dinero o trueque]? 
________________ 
     8.1 Por lo general, ¿a qué precio vende sus cerdos pequeños (cuando ya no maman) 
para que alguien mas los críe o los coma?  
     8.2 Por lo general, ¿a qué precio vende sus pies de cria?  
9. Por lo general, ¿a qué precio vende sus cerditos de 4 meses o menores [Especifique la 
unidad monetaria usada, puede ser dinero o trueque]?   
10. ¿Para qué usa las ganancias de la venta de sus cerdos? [Marque todas las que se 
apliquen] 
 Para enviar a los niños a la escuela   Para comprar comida  
 Para invertir en un negocio    Para ahorrar  
 Otro [Especifique] 
______________________________________________________ 
11. ¿Ha visto o escuchado alguna vez sobre el grano, granillo o tomate de los cerdos? 
 Sí       No [Termina la entrevista] 
 11.1  ¿En que partes del cerdo vivo se pueden encontrar el grano, granillo o tomate?  
 No es posible encontrarlos en un cerdo vivo   
 Debajo de la piel     Debajo de la lengua 
 En la carne      En los ojos 
 En algún otro lugar [Especifique]________________   No lo sé 
 11.2  ¿Cómo le salen el grano, granillo o tomate a los cerdos? 
 Por comer excremento/heces humanas  Por comer excremento/heces de 
cerdo  De otro cerdo infectado     Otro [Especifique] ___________ 
 Por comer semillas de jitomate   No lo sé 
 11.3 ¿Qué haría si descubriera que su cerdo tiene grano, granillo o tomate? 
 Lo vendería    Lo trataría con hierbas 
 Picaría los granos    Otro [Especifique] ________________ 
 No lo sé 
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ÉSTE ES EL FINAL DE LA ENTREVISTA, MUCHAS GRACIAS POR SU 
AYUDA 
 
 
ENTREVISTADOR: _________________________FECHA DE LA 
ENTREVISTA:_________ 
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